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Beyond their ability to produce antibodies,1 B cells produce proinflammatory or anti-inflammatory cytokines,2,3 pres-
ent antigen to T cells,4 and regulate B- and T-cell responses.5 
Mature naive bone marrow (BM)–derived B-2 cells home 
into secondary lymphoid organs (SLOs) where they undergo 
somatic hypermutation and affinity maturation in germinal 
centers (GCs). Antigen-experienced B-2 cells either become 
short-lived plasma cells (PCs) residing in SLOs or they 
develop into long-lived PCs that largely home to the BM.6–8 
By contrast, the majority of B-1 cells are located in the perito-
neal cavity (PerC) and pleural cavities where they form a pool 
of quiescent innate B cells. On migration to inflammatory tis-
sues, B-1 cells become activated and self-renew to carry out 
T-cell–independent protective immune responses.9–12 Recent 
reports showed differential effects of B-cell subsets in ath-
erosclerosis13–24 with antiatherogenic effects of B-1 cells and 
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lymphoid organs (ATLOs). Aging-associated aorta B-cell–related transcriptomes were identified, and transcript atlases 
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Moreover, ApoE−/− mice showed increased germinal center B cells in renal lymph nodes, IgM-producing plasma cells in the 
bone marrow, and higher IgM and anti–MDA-LDL (malondialdehyde-modified low-density lipoprotein) IgG serum titers.
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proatherogenic effects of B-2 cells.25–27 In addition to SLOs 
and the BM, B-cell responses may be organized in artery ter-
tiary lymphoid organs (ATLOs) in apolipoprotein E-deficient 
(ApoE−/−) mice.28,29 Here, we report on local aorta as opposed 
to systemic B-cell responses during aging.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Aorta B-Cell Transcripts During Aging
MIAME (minimum information about a microarray 
experiment)-compliant microarrays were prepared as 
described30,31; data were deposited in the National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/) 
and the gene ontology (http://www.geneontology.org/) data 
banks (accession GSE40156).30,32 To determine if B-cell–
related gene expression changes with aging, microarrays of aor-
tas, SLOs, and blood from wild-type (WT) and ApoE−/− mice 
were compared. B-cell–related genes were altered in WT aor-
tas during aging (Table I in the online-only Data Supplement). 
However, there were much more pronounced changes in 
ApoE−/− when compared with WT aortas. Expression kinet-
ics of some of these genes correlated with the kinetics of 
ATLO formation32,33 (Figure 1; Table I in the online-only 
Data Supplement). B-cell transcriptomes contained genes that 
were expressed exclusively by B cells and a majority of genes 
that respond to B-cell–derived molecules yielding a complex 
B-cell immunity–related gene map (Figure 1; Table I in the 
online-only Data Supplement). Examples of the magnitude of 
B-cell immunity–related transcripts in ApoE−/− aortas include 
a 135-fold increase of Ighm (IgM constant region), a 29-fold 
increase in Ptpn6 (protein tyrosine phosphatase, nonreceptor 
type 6; SHP1) regulating the IgM repertoire, a 23-fold increase 
in the immunosuppressive Lilrb3 (leukocyte immunoglobulin-
like receptor, subfamily B with transmembrane and immuno-
receptor tyrosine-based inhibitory motif domains), Fcer1g (Fc 
receptor, IgE, high-affinity I, γ-polypeptide), and Cd28 (CD28 
antigen) expression that promotes PC survival (Figure 1; Table 
I in the online-only Data Supplement). In contrast, spleen- and 
blood-transcript maps were considerably smaller, and the 
extent of differential expression between WT and ApoE−/− 
mice was much less pronounced (Figure I in the online-only 
Data Supplement). The majority of B-cell–associated genes 
in the spleen and blood were downregulated during aging 
in both WT and ApoE−/− mice: Ptprc (B220; Cd45; protein 
tyrosine phosphatase, receptor type, C) involved in cell fate 
decisions of the B-cell receptor; Aicda (activation-induced 
cytidine deaminase) regulating somatic hypermutation and Ig 
class switching; Sykb (spleen tyrosine kinase) participating 
in B-memory cell survival; Vav3 (Vav3 oncogene) mediating 
B-cell receptor responses; Tcf3 (transcription factor 3) con-
trolling B-cell ontogeny; Foxp1 (forkhead box p1) impacting 
B-cell survival; and Malt1 (Malt1 paracaspase) participating 
in B-cell malignancies. In summary, the spleen and blood 
gene maps suggested that age-associated changes largely mir-
rored B-cell senescence rather than genotype/hyperlipidemia-
dependent changes (Figure I and Table I in the online-only 
Data Supplement).
Transcript Maps Delineate the Territoriality 
of B-Cell–Related Immune Responses 
in the Aged ApoE−/− Aorta
Laser capture microdissection aorta-derived tissues were 
obtained together with renal lymph nodes (RLNs) and 
spleen.30,31 B-cell–related genes were expressed at higher lev-
els in ATLOs when compared with aorta adventitia segments 
from WT or ApoE−/− mice without plaques (Figure 2A; Table 
I in the online-only Data Supplement). In the adventitia clus-
ter, genes associated with B-cell survival, proliferation, dif-
ferentiation, and activation, such as immunoglobulin genes 
(ighm), TACI (tnfrsf13b), B-cell activating factor receptor 
(tnfrsf13c), CD40 antigen (cd40), histocompatibility 2, class 
II antigen A, β-1 (h2-ab1), complement components (c1qb), 
and Myd88 (myd88) were robustly expressed in adventi-
tial regions adjacent to plaques compared with adventitia in 
regions with no plaques (Figure 2A; Table I in the online-
only Data Supplement). Moreover, the adventitia adjacent to 
plaques contained transcripts coding for Igj chain (immuno-
globulin joining chain; Igj) involved in somatic hypermutation 
and memory B-cell development; CD79a (immunoglobulin-
associated α; Ly54) involved in B-cell receptor signaling; and 
Ms4a1 (CD20) controlling T-cell–dependent humoral immu-
nity (Figure IIA in the online-only Data Supplement). The 
plaque–ATLO cluster markedly expressed Cd19 (CD19 anti-
gen) in ATLOs involved in B-cell maturation, Cd20, Igj chain, 
Igm, and Cd79a/b (Figure 2B; Figure IIB in the online-only 
Data Supplement). In addition, the plaque–ATLO B-cell clus-
ter30,31 showed functional separation in B-cell–related genes 
in ATLOs versus plaques: bona fide B-cell genes displayed 
strong expression in ATLOs versus low expression in plaques. 
For example, Ighm, cd19, ms4a1 (cd20), Igj, and cd79a/b 
were expressed manifold higher in ATLOs when compared 
with plaques, which expressed genes that respond to B-cell 
products (Figure 2A; Figure IIB and Table I in the online-only 
Data Supplement). In contrast, the transcript atlas showed 
almost identical levels of B-cell–related genes in WT versus 
ApoE−/− spleens, RLNs, and blood (Figure I in the online-only 
Data Supplement; Figure 2C and 2D). It is also noticeable that 
the LN–ATLO cluster shows a comparably higher expression 
in ATLOs versus LNs of innate immune response genes, such 
as fcgr1, fcgr2b, fcgr3, c4b, and the c1q family, indicating 
ongoing inflammation in ATLOs (Figure 2C and 2D).
Nonstandard Abbreviations and Acronyms
ATLOs artery tertiary lymphoid organs
BM bone marrow




RLNs renal lymph nodes
WT wild-type
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ATLO B-2 Subtypes Suggest Antigen-
Specific GC Reactions
B cells present in the aorta of aged ApoE−/− mice predomi-
nantly reside in ATLOs, whereas they cannot be observed in 
plaques of young WT or ApoE−/− mice.30,32,33 Fluorescence-
activated cell sorting (FACS) analyses of B cells revealed the 
magnitude of differences in ATLOs and WT adventitia; and 
B220 immunostaining confirmed that B cells are located in 
ATLOs and in the adjacent draining LNs but none in WT 
adventitia or plaques (Figure 3A and 3B). Considerable num-
bers of T-/B-cell clusters referred to as fat-associated lym-
phoid clusters were observed in paraaortic adipose tissue of 
aged ApoE−/− mice and numerous small paraaortic LNs con-
taining B cells lined the tissue adjacent to the adventitia (not 
shown). There were no differences in the frequency of B cells 
in SLOs or blood of WT versus ApoE−/− mice (Figure 3C). 
To obtain evidence for an ongoing GC reaction in ATLOs, 
CD19, IgM, and IgD antisera together with FACS gating 
for 4 different populations from CD19+ B cells were used 
(Figure 3D). IgM+/IgD−, IgM+/IgD+, IgM−/IgD−, and IgM−/
IgD+ B cells were identified in abdominal but not thoracic 
aorta segments: IgM+/IgD− cells represent either immature or 
transitional B cells (also referred to as T-1 cells) represent-
ing the earliest B-cell stage present outside the BM or these 
cells may represent B-1 B cells34; IgM+/IgD+ and IgM−/IgD+ 
cells represent mature B-cell stages.35,36 Among mature IgD+ 
cells, IgM−/IgD+ are mature follicular B-2 cells.37 IgM−/IgD− 
cells represent either switched Ig+ B cells, GC B cells that 
have transiently lost Ig expression when undergoing hyper-
mutation of their Ig genes or GC-derived memory B cells.34,38 
Figure 1. Aging-associated changes in aorta B-cell immunity. A, Age-associated transcript profiles of wild-type (WT) and ApoE−/− aorta 
of 6-, 32-, and 78-week-old mice (3 mice per genotype per age group). Transcripts in gene ontology terms immune system process, 
B-cell–mediated immunity, B-cell activation, positive regulation of B-cell–mediated immunity, positive regulation of B-cell activation, B-cell 
proliferation, and B-cell differentiation are displayed as heatmaps. B, Expression of selected genes in aorta from WT and ApoE−/− mice 
at 6, 32, and 78 weeks; n=3 mice per genotype per age group. Results represent mean±SEM. Analyses were performed using ANOVA 
with Benjamini–Hochberg correction. Absolute numbers of signal intensities and statistics are reported in Table I in the online-only Data 
Supplement.
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Figure 2. Aorta transcript maps reveal the specificity and territoriality of B-cell–related immune responses in artery tertiary lymphoid 
organs (ATLOs). A, Heatmaps of differentially expressed genes in the adventitia cluster (wild-type [WT], n=3; ApoE−/−, n=4). B, Plaque/
ATLO cluster (for plaque, n=3; for ATLOs, n=4). C, Lymph node (LN) cluster (for WT and ApoE−/− LNs, n=3; for ATLO, n=4); (Continued) 
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None of the subsets were found in the abdominal aorta of 
WT mice (Figure 3D). WT and ApoE−/− SLOs and blood 
revealed equivalent numbers of these subsets with the excep-
tion of an increase in transitional IgM+/IgD− B cells in RLNs 
of ApoE−/− versus WT mice (Figure 3E). We determined the 
percentages of IgM+/IgD+ or switched Ig+ B cells in SLOs, 
blood, WT aortas, and ATLOs. SLO and blood IgM+/IgD+ 
and switched Ig+ B cells were similar in WT and ApoE−/− 
SLOs (Figure 3F and 3G). Although undetectable in WT 
adventitia, the percentage of IgM+/IgD+ B cells in ATLOs 
Figure 2 Continued. gene ontology terms immune system process, B-cell activation, B-cell–mediated immunity, immunoglobulin, positive 
regulation of B-cell–mediated immunity, positive regulation of B-cell activation, B-cell differentiation, and B-cell proliferation. D, Selected 
genes in the LN cluster. Results represent mean±SEM. Analyses were performed using ANOVA with Benjamini–Hochberg correction. 
Absolute numbers of signal intensities and statistics are reported in Table I in the online-only Data Supplement. RLN indicates renal LNs.
Figure 3. Artery tertiary lymphoid organs (ATLOs) harbor a diverse repertoire of B-cell subsets. A, Flow cytometry of CD19+ B cells of total 
CD45+ leukocytes in abdominal aorta of 80-week-old wild-type (WT) and ApoE−/− mice (WT, n=11; ApoE−/−, n=10). B, Immunofluorescence 
staining with anti-B220 antisera shows B cells in ATLOs and lymph nodes (LNs) but none in the media (M) or plaque (P) or in WT adven-
titia. C, B cells in the spleen, renal LNs (RLNs), and blood of WT and ApoE−/− mice (WT, n=8; ApoE−/−, n=6). Flow cytometric analysis of 
IgM+IgD−, IgM+IgD+, IgM−IgD−, and IgM−IgD+ B cells per total CD19+ B cells in abdominal aorta (D) and spleen, RLN, and blood of 80-week-
old WT and ApoE−/− mice (WT n=4; ApoE−/− n=5; E). Percentages of IgM+IgD+ B cells (F) and IgM−IgD− B cells per total B cells in ATLOs, 
spleen, RLN, and blood of age-matched WT and ApoE−/− mice (G). Results represent mean±SEM; *P<0.05, **P<0.01, and ***P<0.001; 
2-sided unpaired Student t test. n indicates the number of experiments; n.d., not detectable; ns, not significant; and SSC, side scatter.
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approached that in SLOs (Figure 3F). However, the percent-
age of switched Ig+ B cells in ATLOs exceeded those in SLOs 
or blood (Figure 3G). We determined the number of B-1 cells 
in the PerC and of plasmablasts and PCs in the abdominal 
aorta, spleen, and RLNs of ApoE−/− mice (Figure III in the 
online-only Data Supplement). No change in B-1 B cell sub-
types was observed in the PerC of WT versus ApoE−/− mice 
(Figure IIIA in the online-only Data Supplement). Moreover, 
aged ApoE−/− abdominal aortas, spleens, and RLNs contained 
plasmablasts and PCs; some of which expressed interleukin 
(IL)-10 (Figure IIIB in the online-only Data Supplement).
ATLOs Harbor GC B Cells and IgG1+, 
IgA+, and IgE+ Memory Cells
Naive B cells in SLOs enter GCs to undergo a GC reaction 
involving somatic hypermutation and affinity maturation of their 
B-cell receptors. ATLO GC B cells were identified by FACS 
(IgD−/PNA+/GL-7+): they were undetectable in WT aortas but 
Figure 4. Artery tertiary lymphoid organs (ATLOs) contain B cells that participate in humoral immune responses. A, IgD− B cells gated 
from CD19+ total B cells were evaluated for PNA+/GL-7+ (germinal center [GC] B cells) in ATLOs. B, GC B cells in ATLOs and SLOs were 
quantified (wild-type [WT], n=4; ApoE−/−, n=5). C, IgG1+ (IgG1+/CD38+), IgA+ (IgA+/CD38+), and IgE+ (IgE+/CD38+) memory B cells were 
gated from total CD19+/IgD− B cells. D, Quantification of IgG1+, IgA+, and IgE+ memory B cells in ATLOs, SLOs, blood, and bone marrow 
(BM; WT, n=4; ApoE−/−, n=4). Results represent mean±SEM; *P<0.05, 2-sided unpaired Student t test. E, Immunofluorescence data of IgE+ 
memory B cells (IgE+/B220+ indicated with arrows and IgE+/B220− cells indicated with arrow heads), IgA+ memory B cells (IgA+/B220+), 
long-lived plasma cells (PCs; CD138+/BrdU−) and short-lived PCs (CD138+/BrdU+; white arrow), IgM- (IgM+/CD138+), and IgG1- (IgG1+/
CD138+) producing PCs in ATLOs. Dotted line outlines media. n indicates the number of experiments; n.d., not detectable; ns, not signifi-
cant; P, plaque, and RLN, renal lymph node.
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ranged at ≈9% of all IgD− B cells in ATLOs (Figure 4A and 4B). 
Their number was similar in WT and ApoE−/− spleen and blood 
although they were more abundant in ApoE−/− when compared 
with WT RLNs (Figure 4B). We sought evidence for isotype-
switching using FACS analyses. Surprisingly, we observed 
significant numbers of CD19+/IgD−/IgG1+, CD19+/IgD−/IgA+, 
and CD19+/IgD−/IgE+ B cells in ATLOs (Figure 4C and 4D). 
Although class switching is not restricted to GCs, the presence of 
GCs and cells that class switched to T-dependent Ig subclasses, 
such as IgG1, suggests that these cells resemble memory B cells. 
Intriguingly, the percentage of IgD− B cells that class switched to 
IgG1 was significantly greater than those in the spleen, RLNs, 
BM, or blood (Figure 4D). In contrast, there were equivalent 
percentages of IgG1+ B cells in the spleen, BM, and blood of 
WT versus ApoE−/− mice. Consistent with rare ATLO formation 
in the thoracic aorta,32 no GC B cells or class switched B cells 
were observed there (not shown). These data provide evidence 
for a disease-specific antigen-dependent B-2 B cell maturation 
pathway in ATLOs.
Short-Lived and Long-Lived PCs in ATLOs
Long-lived PCs are major constituents of humoral memory. 
Long-lived PCs preferentially home to the BM, whereas 
short-lived PCs remain within SLOs. Nothing is known about 
PCs in atherosclerosis. As long-lived PCs survive for long 
periods of time in the BM,39 we determined the composition 
of ATLO PC subtypes.8 Both long-lived and short-lived PCs 
were observed in ATLOs (Figure 4E).40,41 Moreover, survival 
factors for long-lived PCs, including CXCL12, B-cell activat-
ing factor,39 and others, are markedly expressed in ATLOs30,32 
(Table I in the online-only Data Supplement).
ATLOs Promote B-2 and B-1 Cell 
Recruitment Into the Arterial Wall
To determine B-cell recruitment by ATLOs, we adoptively trans-
ferred Ly5.1 B-2 cells to aged Ly5.2 WT or ApoE−/− mice. After 
36 hours, B-2 cells had migrated predominantly to the abdominal 
aorta of ApoE−/− mice (Figure 5A and 5B) although none were 
recruited to WT aortas. Comparably low but similar numbers of 
Figure 5. Artery tertiary lymphoid organs (ATLOs) promote B-2 B-cell recruitment into the abdominal aorta, skewing of ATLO B-1 cells 
toward B-1b cells. Fluorescence-activated cell sorting (FACS)–purified Ly5.1+ CD19+/CD43− B-2 cells (purity, >98%) were adoptively 
transferred via tail vein injection into aged wild-type (WT) or ApoE−/− mice. Thirty-six hours later, Ly5.2+ recipient mice were analyzed for 
B-2 cell migration into ATLOs or thoracic aorta segments. A, Migrated B-2 B cells were gated from total B cells in ATLOs. B, Quantifica-
tion of migrated Ly5.1+ B-2 B cells in aorta. C, Peritoneal cavity (PerC), spleen, renal lymph nodes (RLNs), and bone marrow (BM). Results 
represent mean±SEM; *P<0.05, 2-sided unpaired Student t test. WT, n=3; ApoE−/−, n=3. B-1 cells selectively accumulate in ATLOs. D, 
IgMhi/CD43+ B-1 cells were gated from CD19+ B cells, and CD5+ B-1a and CD5− B-1b cells were gated from total B-1 cells in ATLOs and 
the percentage of B-1 cells from total B cells were quantified in ATLOs and SLOs. E, Absolute numbers of B-1 cells were quantified in 
aortic segments in WT and ApoE−/− mice. The ratio of B-1b/B-1a B cells in ATLOs compared with that in PerC of WT and ApoE−/− mice. 
FACS plots show the gating strategy for B-cell subpopulations in PerC (F) and their frequencies of B cells in CD45+ cells, B-1, and B-2 
cells in total B cells, B-1a, and B-1b cells in B-1 cells were compared between WT and ApoE−/− mice (G). Results represent mean±SEM; 
**P<0.01 and ***P<0.001; 2-sided unpaired Student t test with Bonferroni–Holm correction. WT and ApoE−/−, n=5–6. n indicates the num-
ber of experiments; n.d., not detectable; ns, not significant; and SSC, side scatter.
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B-2 cells were recruited into the PerCs of WT and ApoE−/− mice. 
There was no difference in B-cell recruitment into the spleen, 
RLNs, and BM of WT versus ApoE−/− mice (Figure 5C). Similar 
data were obtained with B-1 cells (not shown).
B-1 Cells Accumulate in ATLOs and 
Are Skewed Toward B-1b Cells
B-1 cells are predominantly located in body cavities.42,43 Recent 
studies showed that B-1a cells reside in the aorta perivascular tis-
sue of young ApoE−/− mice.22 To determine if B-1 cells are located 
in the aged aorta adventitia, we performed FACS analyses. A high 
percentage of all B cells, that is, ≈21%, in ATLOs were B-1 cells 
(Figure 5D), and their relative contribution to all B cells exceeded 
that in the spleen and RLNs by a large margin (Figure 5D). The 
reason for B-1 B-cell accumulation is most likely the high expres-
sion of CXCL13 in ATLOS. Numbers of total B-1 cells in ATLOs 
are comparable with that of IgM+/IgD− cells, indicating that most 
IgM+/IgD− cells found in this compartment are B-1 cells. The 
abdominal aorta harbored considerably higher numbers of B-1 
cells when compared with the thoracic aorta (Figure 5E). The B-1 
subtype composition was aberrant as we observed a high number 
of B-1b versus B-1a cells, which dramatically differs from that 
relation in the PerC (Figure 5E).9 There was no significant differ-
ence in total B cells, B-2, B-1a, and B-1b cells in the PerC of aged 
WT and ApoE−/− mice (Figure 5F and 5G).
Majority of ATLO B-1b but Not B-2 
Cells Express IL-10, PD-L1, FasL, and 
Transforming Growth Factor-β
In view of skewing of ATLO B-1 cells toward the B-1b sub-
type (Figure 5D and 5E) and a recent report showing that 
B-1b cells protect against atherosclerosis,21 we searched for 
Figure 6. Artery tertiary lymphoid organ (ATLO) B-1 B cells show a predominant immunosuppressive IL-10+/PD-L1+/FasL+/TGFβ+ pheno-
type. Cell suspensions from individual aged ApoE−/− mice. A, IL-10+, TGFβ+, PD-L1+, and FasL+ abdominal aorta B cells. B, ApoE−/− (red) 
spleen (80- to 85-week old mice) and WT (blue); ApoE−/− (n=3–4). B-1a, B-1b, and B-2 cell populations were gated and assayed for cyto-
kine expression (or isotype control, black). Numbers designate frequencies of positive cells.
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mechanisms of immunosuppression within the arterial wall. 
IL-10–producing B-1a rather than B-1b or B-2 cells were found 
in the PerC (Figure IIIA in the online-only Data Supplement). 
However, we observed that the majority (≈72%) of abdominal 
aorta B-1b cells produced IL-10 though a minor component of 
B-1a cells and a significant but low proportion of IL-10+ cells 
in the thoracic aorta (not shown). No or comparably low num-
bers of B-1a cells or B-2 cells expressed IL-10 (Figure 6A). 
Moreover, the frequency of IL-10+ B cells in ATLOs is higher 
than those of their counterparts in the spleen and RLNs of 
WT or ApoE−/− mice (Figure 6B). Following a report that a 
subset of PCs secretes IL-10,44 we assessed IL-10 expression 
in PCs. A significant proportion of ATLO CD138+/CD19+ 
plasmablasts were IL-10+ PCs (Figure IIIB in the online-only 
Data Supplement). Similar PCs have been shown to suppress 
immune responses in disease models.45 We further assessed 
the phenotype of B-1 cells in the abdominal aorta. ATLO B-1 
but to a much lesser extent B-2 cells expressed PD-L1, FasL, 
and transforming growth factor-β, indicating that these cells 
exert immunosuppressive functions (Figure 6A).
Ig-Secreting Cells Accumulate in ATLOs
ELISPOT (enzyme-linked immunospot) experiments were 
performed. There were no constitutively IgM- and IgG-
secreting cells in either the thoracic or abdominal aorta of 
WT mice (Figure 7A and 7B). Few IgM- and IgG-secreting 
cells were observed in the thoracic aorta of ApoE−/− mice 
(Figure 7A and 7B). However, ATLOs contained abundant 
IgM- and IgG-secreting cells amounting to ≤80-fold increase 
of IgM-secreting B cells and a 24-fold increase in IgG-
secreting B cells in the abdominal aorta (Figure 7A and 7B). 
Blood contains few (<10 cells per 0.5 mL of blood) IgM- or 
Figure 7. IgM- and IgG-secreting B cells are selectively located in artery tertiary lymphoid organs (ATLOs). A, ELISPOT (enzyme-linked 
immunospot) analyses of IgM- and IgG-secreting B cells in ATLOs and thoracic aorta segments. B, Quantification of IgM- and IgG-secret-
ing cells in ATLOs versus thoracic aorta. C, Quantification of IgM-secreting cells in the spleen, renal lymph node (RLN) and bone marrow 
(BM) of age-matched wild-type (WT) and ApoE−/− mice. D, Serum titers of IgM, IgG, and IgE in aged WT and ApoE−/− mice. E, Anti–MDA-
LDL IgM and anti–malondialdehyde-modified low-density lipoprotein (MDA-LDL) IgG serum titers (dilution factor 10 and 25, respectively) 
in aged WT and ApoE−/− mice. Results represent mean±SEM; 2-sided unpaired Student t test; n=10 per genotype; *P<0.05 and **P<0.01. 
ns indicates not significant.
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IgG-secreting cells (data not shown). In the spleen and RLNs, 
there was no difference in Ig-secreting cells between WT and 
ApoE−/− mice (Figure 7C). However, IgM-secreting cells were 
higher in ApoE−/− BM when compared with WT BM raising 
the possibility of a systemic PC response in ApoE−/− mice. 
To examine a systemic B-cell response, we determined serum 
titers of IgM, IgG, and IgE, as well as anti–malondialdehyde-
modified low-density lipoprotein (MDA-LDL) IgM and IgG. 
Aged ApoE−/− mice had significantly higher levels of total 
IgM but not IgG or IgE levels when compared with aged WT 
mice (Figure 7D). Although anti–MDA-LDL IgM levels were 
not different, anti–MDA-LDL IgG levels were significantly 
higher in ApoE−/− versus WT mice (Figure 7E).
Discussion
These data identify ATLOs as the principal lymphoid tissue that 
orchestrates atherosclerosis B-cell immunity during aging of 
ApoE−/− mice. Atherosclerosis ATLO B-cell responses are spe-
cific, robust, highly territorialized, multilayered, and include a 
comprehensive adaptive B-2 and a substantial aberrant innate 
B-1 cell component: ATLOs but not WT adventitia harbor an 
unusual set of class-switched IgG1+, IgA+, and IgE+ B cells, a 
significant number of IL-10+/PD-L1+/FasL+/TGFβ+ B-1b cells, 
and both short-lived and long-lived PCs, including a fraction 
of IL-10+ PCs. This body of data—together with our previous 
observation that B cells are major constituents of ATLO anti-
gen-presenting cells30—reveal a yet unrecognized scenario of 
aorta atherosclerosis-specific B-cell immunity, which includes 
B effector cells, PCs, and several immunosuppressive B-cell 
subtypes (Figure IV in the online-only Data Supplement).
ATLO B-2 B-cell subtypes include transitional, follicular, 
GC, and IgG1+, IgA+, and IgE+ B cells—the latter representing 
class-switched B cells and PCs. These data are the first to sug-
gest that (auto)antigen-dependent hypermutation, proliferation, 
affinity maturation, Ig class switching, memory cell generation, 
and differentiation into long-lived PCs may be carried out in the 
arterial wall. It is becoming evident that ATLOs provide a new 
paradigm of atherosclerosis-specific B-cell immunity and pos-
sibly autoimmunity: ATLO B-cell responses occur in aged ani-
mals, whereas aortas of young ApoE−/− or young and aged WT 
mice do not show a significant aorta B-cell compartment.30,46–48 
It should be pointed out, however, that this study falls short of 
proving antigen-specific ATLO-dependent autoimmune B-2 
B-cell generation. In this regard, the observation of a consider-
able number of PCs in ATLOs deserves special attention: PCs 
may arise from B-1 cells, from B-2 cells via T-cell–independent 
mechanisms, or from B-2 cells via T-cell–dependent mecha-
nisms.49 Further studies on the origin of aorta PCs seem war-
ranted as the role of PCs in atherosclerosis remains unknown.
Our data demonstrate that local B-cell immune subsets can 
be distinguished from those in SLOs, the PerC, and the BM: 
their aberrant nature manifests itself by the presence of large 
numbers of IL-10+ B-1b cells, of short-lived and long-lived PCs, 
and of IL-10+ PCs. Possibly, our aged mice will allow to isolate 
B cells from ATLOs and SLOs to compare their B-cell recep-
tor repertoire. Moreover, the accumulation of IgA+ and IgE+ 
B cells in the diseased aorta indicates links of atherosclerosis 
B-cell immunity to innate inflammatory leukocytes in plaques. 
IgA, IgE, and IgG act through either activating or inhibitory 
Fc receptors on virtually all innate immune cells, including 
macrophages.50 The expression of divergent Fc receptors raises 
the possibility that Fc receptors may be involved in the dicho-
tomic control of inflammation within diseased arteries: Fcer1g 
(Cd23) is a high-affinity IgE receptor that is upregulated during 
aging, and Fcgr1 (Cd64), Fcgr2b (Cd32), and Fcgr3 (Cd16) are 
prominently expressed in ATLOs.
ATLOs contain multiple B-cell subtypes, including IgM+/
IgD−, IgM+/IgD+, IgM-/IgD−, and IgM−/IgD+ B cells. ATLO 
IgM+/IgD− and IgM+/CD43+ B cells may be B-1 cells. In 
addition, the presence of class-switched memory B cells 
suggests that some ATLO IgM+/IgD− B cells may represent 
IgM+ memory B cells that have not undergone class switch-
ing. IgM+ memory B cells considerably contribute to the total 
population of all memory B cells.51 Whether the population 
of IgM+/IgD− B cells within ATLOs also includes a fraction 
of immature or transitional B cells that represent the earli-
est B-cell stages that are found outside the BM is a possibil-
ity that deserves attention. Under physiological conditions, 
immature B cells immigrate from the BM and specifically 
home to splenic follicles to undergo differentiation into a 
transitional B-cell stage and finally either become mature 
B-2 or marginal zone B cells.52 This final B-cell maturation 
is accompanied by a shift of the B-cell receptor repertoire 
that includes counterselection against autoreactive cells that 
occurs in discrete and tightly controlled steps.53 Hence, it is 
tempting to speculate that immature B cells home to ATLOs 
to undergo differentiation into mature B cells in the absence 
of the proper control mechanisms acting in the spleen: this 
could allow for the generation of autoreactive atherosclero-
sis-specific B cells.
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 Hypothetical choreography of ATLO B cell responses.  Mature naïve B-2 or circulating B-
1 cells enter ATLOs through high endothelial venules (HEVs). B-2 cells undergo T helper 
cell-dependent activation, proliferation, and maturation steps including somatic 
hypermutation and affinity maturation in germinal center reactions in response to arterial 
wall-derived autoantigen(s). The resulting high-affinity B-2 B cells either differentiate into 
memory B cells followed by isotype-switching and/or differentiation into plasma cells. A 
fraction of plasma cells expresses IL-10+. B-1 cells are activated by inflammatory cytokines 
and - possibly in response to atherosclerosis autoantigens - undergo self-renewal to form IL-
10- B-1a or IL-10+ B-1b cells. T cell immune responses except T helper cells and T follicular 
helper cells or antigen-presenting cells are not depicted for ease of reading. 
 
 
Materials and Methods 
 
Mice. C57BL/6J WT and ApoE-/- mice were purchased from the Jackson laboratory and 
housed in the animal facilities of University of Jena and Ludwig-Maximilians-University 
Munich Germany. Mice were maintained in a pathogen-free environment on a 12 hour 
light/dark cycle and fed standard chow. 78-80 weeks old male WT and ApoE-/- mice 
were used. CD45.1/Ly5.1 mice were bred in the animal facility of the Leibniz-Institute for 
Age Research Jena, Germany. Animal procedures were conducted according to 
guidelines approved by the Animal Care and Use Committees. 
 
Single cell preparation from aorta, spleen, RLN, blood, PerC, and BM. Single cell 
suspensions from aorta were prepared by enzymatic digestion as previously described1 
with further modifications as described1, 2. Briefly, WT and ApoE-/- mice were euthanized 
and the aorta was perfused with 2 mM EDTA in PBS, PBS, and FACS buffer. Care was 
taken to remove adjacent adipose tissue and small paraaortic lymph nodes to avoid 
contamination with cells present in adjacent connective tissues including fat associated 
lymphoid clusters. Thoracic and abdominal aorta segments were harvested, cut into 
small pieces and digested in 2.5 ml of enzyme cocktail (450 U/ml collagenase type I, 
125 U/ml collagenase type XI, 60 U/ml hyaluronidase and 60 U/ml DNase1) in 
Dulbecco’s phosphate buffered saline (DPBS) containing 20 mM HEPES. Digestion was 
carried out at 37° C for 1 hour in a water bath with shaking. The cell suspension was 
filtered through a 70 µm cell strainer by mashing aorta pieces using a syringe plunger. 
The cell suspension was centrifuged and resuspended in FACS buffer. Cell 
suspensions from spleen and RLNs was prepared using a 70 µm cell strainer and 
mashing spleen and RLNs with a syringe plunger and dissolved in FACS buffer. For 
blood samples, blood (0.2 ml) was collected into 5 mM Na2-EDTA in an Eppendorf tube, 
mixed, centrifuged, and washed. For BM, femurs and tibiae were prepared and the 
muscle was removed. After cutting the ends of femur and tibia, BM was flushed with 
FACS buffer, centrifuged, and washed. Spleen, BM, and blood samples were 
resuspended in erythrocyte lysis buffer and washed. After centrifugation, cells were 
washed and resuspended in FACS buffer and cells were counted. For PerC, peritoneal 
lavage was collected, washed, centrifuged, and resuspended in FACS buffer and cells 
were counted.  
 
Detection and quantification of ATLOs. ATLOs were identified and their size was 
determined as previously described1-3. 
 
Flow cytometry. Fc receptors were blocked by pretreatment with purified anti-mouse 
CD16/32 mAb for 10 min at 4° C. Cells were incubated with fluorescent labelled 
antibodies for 25 min at 4° C and washed twice. Cells were incubated with streptavidin 
conjugate for 20 min at 4° C. After washing, 8-color FACS measurements were 
performed on FACSCanto IITM (BD Bioscience). Data were analysed using FlowJo (tree 
star). Labelled Abs that were used for FACS analyses: CD16/32 (93) (Fc-block); CD45-
PerCpCy5.5 (30-F11); CD45.1-PerCpCy5.5 (A20); CD19-APC (ID3); CD19-eFluor 450 
(ID3); CD23-FITC (B3B4), CD5-PE (53-7.3); CD43-Biotin (R2/60); CD11b-eFluor 450 
(M1/70); CD38-PerCp eFluor-710 (90); PNA-FITC; GL7-Biotin (GL7); IgM-PECy7 
(II/41); IgD-eFluor 450 (11-26c); IgG1-FITC (A85-1); IgA-PE (mA-6E1); IgE-Biotin 
(23G3) and Streptavidin-APC eFluor780; IL-10-PE(JES5-16E3); CD5-APC(53-7.3); 
TGF beta 1–PE; FasL-FITC; PD-L1-PE. All Abs are from eBioscience except PNA-FITC 
(Vector) and IgG1-FITC, CD138-APC (281-2) (BD Biosciences). All antisera were used 
at 1:200 dilutions for staining except PNA-FITC and GL7-Biotin at 1:300.  
 
BrdU labeling and immunofluroscence staining. ApoE-/- mice (78-80 weeks) were 
fed with BrdU (1 mg/ml; Sigma-Aldrich) and 1% glucose (Merck) in drinking water for 2 
weeks. Drinking water was protected from light and changed every 3 days4. After BrdU 
treatment, mice were euthanized and perfused with 3% paraformaldehyde (PFA) in 1x 
PBS at 120 Hg pressure for 30 min at RT. Fresh frozen tissue blocks were prepared for 
aorta and 10 µm sections were prepared for immunofluorescence analyses. Sections 
were washed with PBS for 10 min. To denature DNA, sections were incubated with 2 N 
HCl at 37° C for 15 min (only for BrdU staining) and washed 3 x 5 min with PBS.  A 
blocking step was performed at RT for 1 hour in blocking solution (5% FBS, 1% BSA 
and 0.4% Triton X-100 in PBS). After blocking without washing, sections were incubated 
overnight with primary antibodies at 4° C. After primary antibody staining, sections were 
washed and incubated with fluorescent labelled secondary antibodies and DAPI at RT 
for 60 min. Sections were washed and mounted onto slides using fluorescence 
mounting medium (S3025, Dako). Immunofluorescence analyses were performed as 
described1 using primary antibodies CD138 (1:50, R&D), BrdU (1:50, Oxford 
Biotechnology), CD45R/B220 (1:200, BD), IgG1-FITC (1:50, BD), IgM-FITC (1:50, BD), 
IgA-PE (1:50, eBioscience), IgE-Biotin (1:50, eBioscience), and corresponding 
fluorescent labelled secondary antibodies (1:300, all from Dianova).. For negative 
controls, stainings were performed without primary antibodies. Pictures were taken by 
LSM-510 META confocal scanning microscope (Zeiss) or SP5 (Leica) and analysed by 
Zeiss LSM image browser or Fiji image processing softwares.  
 
MACS and ELISPOT assay. To identify constitutively IgM- and IgG-secreting B cells, 
ELISPOT assays were performed. Single cell suspensions of aortas were incubated 
with CD45 microbeads for 15 min at 4° C. Cells were washed, centrifuged and the pellet 
was resuspended in MACS running buffer. CD45+ cells were separated using the 
POSSEL-S program in Auto-MACS (Miltenyi Biotec) and purified >97%. MultiScreenHTS 
IP-Plates (MSIPS4510, Millipore) were used. Each well was rinsed according to 
manufacturer’s protocol. After washing, wells were coated with unlabelled anti-mouse 
IgM or IgG antisera (10 µg/ml, Southern Biotech) and incubated overnight at 4° C. The 
antibody solution was decanted, wells were washed and blocked with RPMI-1640 + 
10% FCS for 2 hours at 37° C. Cells were washed in cold complete RPMI-1640 medium 
to minimize background and a suspension of 106 cells/ml was prepared. After blocking, 
0.25 x 106 cells from each tissue was added to the wells except for the aorta where total 
sample was added to the well and incubated overnight at 37° C. After 24 hours, cell 
culture dishes were decanted and washed with 0.1% Tween-20 in PBS. Biotin-labelled 
anti-mouse IgM or IgG antibody was (1:500, Southern Biotech) added to each well and 
incubated for 2 hours at 37° C. Plates were washed and streptavidin alkaline 
phosphatase (3:100, Abcam) was added to each well and incubated for 20-30 min at 
RT. Plates were washed, BCIP/NBT was added and incubated until spots became 
visible. Pictures were taken under the dissection microscope (AxioCam dissection 
microscope, Zeiss) and spots were counted manually. 
 
Cell stimulation for IL-10 staining. Cell stimulation and IL-10 staining were performed 
as described5. 
 
Adoptive B cell transfer experiments. B-2 B cell migration into ATLOs were 
determined following transfer of FACS-sorted B-2 B cells (>98% purity). 8 - 10 weeks 
old male CD45.1 (Ly5.1) mice (n=3-4 mice/sort) were used as donors. Spleens from 3-4 
mice were pooled and single cells were prepared. Cells were stained with anti-CD19 
APC, anti-CD43 PE, incubated, washed and DAPI-/CD19+/CD43- B-2 B cells were 
sorted using a BD FACS Aria at a purity of >98% of total live cells. 30x106 cells per 
mouse were injected into aged ApoE-/- or WT mice by tail vein injection. After 36 hours, 
mice were analysed for migrated Ly5.1+ B-2 B cells in PerC, spleen, RLNs, BM, and 
aorta.  
 
Laser capture microdissection (LCM) and microarray analysis. LCM and microarray 
analysis has been done as previously described3, 6, 7. Briefly, total aorta microarray 
analyses were performed on Affymetrix mouse whole genome 430 2.0 microarrays. 
Laser capture-derived RNA microarray analyses were performed with Affymetrix mouse 
whole genome 430A 2.0 microarrays. Signal intensities were calculated from the raw 
data and scaled to an array trimmed mean of 500. All further steps were performed 
using R and Bioconductor (R Development Core Team; Gentleman RC, et al. 2004). 
Logarithmic signals were normalized across arrays of every analysis using quantile 
normalization. Data were filtered prior to statistical analysis to remove genes with low 
expression or without variability between 2 groups: Probe sets were included if at least 
2 arrays per group were called present (detection P≤0.05) and 2 or 3 arrays showed a 
log signal ≥ log2 (200) conditioned on a foldchange of at least log2 (2.0) between 
groups. To correct for lamina media RNA contamination in LCM experiments (error 
caused by nearby media tissue) on adventitia or plaque a correction algorhythm was 
performed: Up-regulated genes in WT adventitia, ApoE-/- adventitia, ATLO or plaque 
data were obtained as described6. Using the filtered data a one-factor variance analysis 
(ANOVA) or a two-sided T-test for two independent samples was applied and corrected 
with Benjamini-Hochberg correction for multiple testing. 
 
Serum Antibodies detection by ELISAs. For the detection of total IgM and IgG, 
microtitre plates (Thermo Scientific, England, United Kingdom) were coated with serially 
diluted serum from aged ApoE-/- and WT mice in PBS overnight at 4°C. The next day, 
plates were washed in PBS containing 0.05% tween and subsequently blocked using 
Animal-Free Blocker (Vector Laboratories, Peterborough, UK) for 1 hour at room 
temperature. Plates were subsequently washed and incubated with HRP conjugated rat 
anti-mouse IgM or IgG for 1 hour at room temperature. For the detection of total IgE a 
Ready-SET-Go Kit was used (Affymetrix, eBioscience). Briefly, plates were coated with 
100 µl of anti-mouse IgE monoclonal antibody and incubated at 4°C degrees overnight. 
The next day, plates were washed in PBS containing 0.05% tween and incubated with 
250 µl of blocking buffer at room temperature for 2 hours. After washing, plates were 
incubated with serial dilutions of serum from aged ApoE-/- and WT mice for 4h at room 
temperature. The plates were then washed and incubated with 100 µl of biotin 
conjugated anti-mouse IgE monoclonal antibody at room temperature for 1 hour. After 
the washing the plates were finally incubated with HRP conjugated Streptavidin for 30 
minutes at room temperature. After a final washing step, 100 µl of SureBlueTM TMB 
microwell peroxidase substrate (KPL, Gaithersburg, MD, USA) was added to each well. 
To stop the reaction, 50 µl of 10% hydrochloric acid was added to each well. Using the 
sunrise ELISA reader (Tecan, Mannedorf, Switzerland), plates were read at 450 nm 
with a reference of 630 nm. 
 
Serum anti-malondialdehyde-oxidized-low density lipoprotein (anti-MDA-LDL) 
antibody detection by ELISA. For the detection of anti-MDA-LDL-specific antibodies, 
microtitre plates were coated with 100 µl of 12.5 µg/ml MDA-LDL (Nordic Biosite, 
Propellervagen, Sweden) in PBS overnight at 4° C. Next day, plates were washed, 
blocked and incubated for 4 hours at room temperature with serially diluted serum from 
aged ApoE-/- and aged WT mice. Plates were washed and incubated with HRP- 
conjugated goat anti-mouse IgG and IgM antisera for 1 hour at room temperature. After 
a final washing step, 100 µl of SureBlueTM TMB microwell peroxidase substrate (KPL, 
Gaithersburg, MD, USA) was added to each well. To stop the reaction, 50 µl of 10% 
hydrochloric acid was added to each well. Using the Sunrise ELISA reader (Tecan, 
Mannedorf, Switzerland), plates were read at 450 nm with a reference of 630 nm. 
 
Statistics. Data are expressed as means ± SEM. Data were analysed by two-tailed 
unpaired Student’s t-test. One-way ANOVA with Bonferroni-Holm correction was done 
when multiple comparisons were made. 
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Figure SI: Age-associated B cell gene expression in spleen and blood of WT and ApoE-/- 
mice.  Age-associated transcript profiles were obtained for total spleen and blood from 32 and 
78 weeks old WT and ApoE-/- mice (n=3 mice per genotype per age group). Transcripts in GO 
terms Immune system process, B cell mediated immunity, B cell activation, positive regulation of 
B cell mediated immunity, positive regulation of B cell activation, B cell proliferation and B cell 
differentiation are displayed as heatmaps. Differential age- and genotype-associated gene 
expressions are shown as heatmaps or of selected genes, respectively in total spleen (A, B) and 
in blood (C, D) of WT and ApoE-/- mice. Results represent means±SEM. Analyses were 
performed using ANOVA with Benjamini-Hochberg correction. Absolute numbers of signal 
intensities and statistics are reported in supplementary Table S1. 
 Figure SII: LCM microarray-based gene expression analysis of plaque versus ATLO.  A) 
Differential expression of selected genes in adventitia cluster (WT n=3; ApoE-/- n=4) and B) 
plaque/ATLO cluster (for plaque ApoE-/- n=3; for ATLOs ApoE-/- n=4). Results represent means ± 
SEM. Analyses were performed using ANOVA with Benjamini-Hochberg correction. Absolute 
numbers of signal intensities and statistics are reported in online supplement Table S1 and 
online methods.  
 Figure SIII: IL-10 producing cells in perC, aorta, spleen, and RLN. Isolated cells from 
peritoneal cavity A) aorta, spleen and RLN B) of 80-85w old WT and ApoE-/- mice (n=3 mice per 
genotype) were stimulated as decribed in methods. Cells were stained with different antibodies 
as indicated. A) B-1a, B-1b, B-2 cells; B) PCs, plasmablasts, and CD138- cells were gated and 
examined for IL-10 expression. Numbers on FACS plots are frequencies of positive cells per 
gate.  
 Figure SIV: Hypothetical choreography of ATLO B cell responses.  Mature naïve B-2 or 
circulating B-1 cells enter ATLOs through high endothelial venules (HEVs). B-2 cells undergo T 
helper cell-dependent activation, proliferation, and maturation steps including somatic 
hypermutation and affinity maturation in germinal center reactions in response to arterial wall-
derived autoantigen(s). The resulting high-affinity B-2 B cells either differentiate into memory B 
cells followed by isotype-switching and/or differentiation into plasma cells. A fraction of plasma 
cells expresses IL-10+. B-1 cells are activated by inflammatory cytokines and - possibly in 
response to atherosclerosis autoantigens - undergo self-renewal to form IL-10- B-1a or IL-10+ B-
1b cells. T cell immune responses except T helper cells and T follicular helper cells or antigen-
presenting cells are not depicted for ease of reading. 
Supplementary table I. Transcript maps of aorta, spleen, blood, and RLNs of WT and ApoE-/- mice. 
A. Differential expression of transcripts coding for B cell-immunity regulating genes in WT and ApoE-/- aorta, spleen, and blood  
A1: Aging-aorta: Differential expression of transcripts coding B cell regulating genes in WT and ApoE-/- total aorta (Fig.1). 
A) B cell mediated immunity 
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vs. 6 weeks 
p ANOVA 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 88 124 211 108 189 14621 135.31 < 0.0001 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 49 77 38 34 66 4275 126.80 0.0007 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 82 67 73 51 91 4981 97.95 < 0.0001 
1460188_at Ptpn6 protein tyrosine phosphatase, non-
receptor type 6 
15170 37 51 198 46 567 1324 28.96 < 0.0001 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 543 718 1806 648 992 17344 26.75 < 0.0001 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 444 654 3608 658 1452 15930 24.20 0.001 
1424302_at Lilrb3 leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and 
ITIM domains), member 3 
18733 86 45 107 56 506 1265 22.71 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1418340_at Fcer1g Fc receptor, IgE, high affinity I, 
gamma polypeptide 
14127 507 690 889 382 2708 5707 14.95 < 0.0001 
1425477_x_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 279 361 491 263 1416 3555 13.53 < 0.0001 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 600 957 1072 623 660 7671 12.32 < 0.0001 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 457 616 941 514 2144 5102 9.93 < 0.0001 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 324 357 399 369 1881 3536 9.58 < 0.0001 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 780 1005 1459 782 2234 6399 8.19 < 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, 
receptor type, C 
19264 486 772 990 642 2454 5106 7.95 < 0.0001 
1437025_at Cd28 CD28 antigen 12487 44 83 77 36 151 265 7.29 0.02 
1417063_at C1qb complement component 1, q 
subcomponent, beta polypeptide 
12260 1347 1154 1506 1169 5621 8251 7.06 < 0.0001 
1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 156 174 234 153 627 1066 6.96 < 0.0001 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide 
of major histocompatibility complex, 
16149 1634 2699 4537 1955 7675 11699 5.98 < 0.0001 
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vs. 6 weeks 
p ANOVA 
class II antigen-associated) 
1422527_at H2-DMa histocompatibility 2, class II, locus 
DMa 
14998 230 277 449 231 546 1370 5.92 < 0.0001 
            
1418133_at Bcl3 B cell leukemia/lymphoma 3 12051 42 138 136 80 335 461 5.73 0.0006 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 736 720 1048 705 2176 3922 5.56 < 0.0001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 549 458 690 506 1472 2594 5.13 < 0.0001 
1418021_at C4b complement component 4B (Childo 
blood group) 
12268 1511 2739 2438 1737 6446 8292 4.77 < 0.0001 
1437726_x_at C1qb complement component 1, q 
subcomponent, beta polypeptide 
12260 1568 1745 1897 1774 7646 8089 4.56 < 0.0001 
1417381_at C1qa complement component 1, q 
subcomponent, alpha polypeptide 
12259 1952 1766 1881 1925 6761 8373 4.35 < 0.0001 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 254 277 421 334 907 1444 4.32 < 0.0001 
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 < 0.0001 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 516 538 551 440 1292 1670 3.79 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1418110_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 345 428 498 344 752 1281 3.72 < 0.0001 
1422122_at Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
14128 140 73 232 93 112 342 3.67 0.02 
1449473_s_at Cd40 CD40 antigen 21939 84 45 100 68 145 230 3.39 0.03 
1417597_at Cd28 CD28 antigen 12487 81 91 65 83 114 282 3.39 0.0001 
1434366_x_at C1qb complement component 1, q 
subcomponent, beta polypeptide 
12260 1499 1543 1546 1518 5822 4861 3.20 < 0.0001 
1456694_x_at Ptpn6 protein tyrosine phosphatase, non-
receptor type 6 
15170 449 549 568 367 660 1075 2.93 0.001 
1452535_at Ighm immunoglobulin heavy constant mu 16019 171 163 236 175 123 494 2.82 0.001 
1436625_at Fcgr1 Fc receptor, IgG, high affinity I 14129 150 172 282 182 348 484 2.65 0.001 
1417244_a_at Irf7 interferon regulatory factor 7 54123 253 302 393 266 425 633 2.38 0.0004 
1423543_at Swap70 SWA-70 protein 20947 678 412 468 498 490 977 1.96 0.0008 
1460415_a_at Cd40 CD40 antigen 21939 95 54 83 119 130 222 1.88 0.01 
1424195_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 277 295 192 234 344 410 1.75 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1457664_x_at C2 complement component 2 (within H-
2S) 
12263 357 255 619 365 420 573 1.57 0.002 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 122 162 123 194 244 248 1.28 0.001 
1421818_at Bcl6 B cell leukemia/lymphoma 6 12053 1904 700 919 1243 862 1208 -1.03 0.007 
1450381_a_at Bcl6 B cell leukemia/lymphoma 6 12053 843 384 390 624 366 434 -1.44 0.0005 
 
B) B cell activation 
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vs. 6 weeks 
p ANOVA 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 88 124 211 108 189 14621 135.31 < 0.0001 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 49 77 38 34 66 4275 126.80 0.0007 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 82 67 73 51 91 4981 97.95 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1448576_at Il7r interleukin 7 receptor 16197 9 10 17 21 471 938 45.04 < 0.0001 
1460188_at Ptpn6 protein tyrosine phosphatase, non-
receptor type 6 
15170 37 51 198 46 567 1324 28.96 < 0.0001 
1436312_at Ikzf1 IKAROS family zinc finger 1 22778 40 43 212 35 338 948 27.12 < 0.0001 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 543 718 1806 648 992 17344 26.75 < 0.0001 
1449858_at Cd86 CD86 antigen 12524 15 8 21 11 107 296 25.86 0.001 
1450297_at Il6 interleukin 6 16193 21 10 57 21 290 523 24.46 0.0001 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 444 654 3608 658 1452 15930 24.20 0.001 
1448575_at Il7r interleukin 7 receptor 16197 106 150 203 136 1187 3130 22.99 < 0.0001 
1451780_at Blnk B cell linker 17060 154 188 302 172 1038 2733 15.93 < 0.0001 
1423478_at Prkcb protein kinase C, beta 18751 16 30 23 23 185 358 15.24 < 0.0001 
1423182_at Tnfrsf13b tumor necrosis factor receptor 
superfamily, member 13b 
57916 39 53 123 46 162 647 14.17 < 0.0001 
1425477_x_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 279 361 491 263 1416 3555 13.53 < 0.0001 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 600 957 1072 623 660 7671 12.32 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1450912_at Ms4a1 membrane-spanning 4-domains, 
subfamily A, member 1 
12482 29 44 95 48 52 564 11.67 0.002 
1428787_at Nckap1l NCK associated protein 1 like 10585
5 
130 86 249 159 779 1589 10.00 < 0.0001 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 457 616 941 514 2144 5102 9.93 < 0.0001 
1418830_at Cd79a CD79A antigen (immunoglobulin-
associated alpha) 
12518 112 143 394 127 150 1235 9.73 0.0001 
1426169_a_at Lat2 linker for activation of T cells family, 
member 2 
56743 137 187 162 115 529 1048 9.14 < 0.0001 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 780 1005 1459 782 2234 6399 8.19 < 0.0001 
1460419_a_at Prkcb protein kinase C, beta 18751 250 359 588 265 1076 2126 8.01 < 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, 
receptor type, C 
19264 486 772 990 642 2454 5106 7.95 < 0.0001 
1436649_at Ikzf3 IKAROS family zinc finger 3 22780 59 95 120 86 115 650 7.55 0.0002 
1437025_at Cd28 CD28 antigen 12487 44 83 77 36 151 265 7.29 0.02 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 281 418 374 235 769 1613 6.86 0.003 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1418261_at Sykb spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 < 0.0001 
1423226_at Ms4a1 membrane-spanning 4-domains, 
subfamily A, member 1 
12482 225 213 388 241 240 1570 6.51 < 0.0001 
1422631_at Ahr aryl-hydrocarbon receptor 11622 227 284 231 185 675 1161 6.29 < 0.0001 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide 
of major histocompatibility complex, 
class II antigen-associated) 
16149 1634 2699 4537 1955 7675 11699 5.98 < 0.0001 
1428786_at Nckap1l NCK associated protein 1 like 10585
5 
283 375 583 364 896 2157 5.92 < 0.0001 
1437356_at Gpr183 G protein-coupled receptor 183 32101
9 
103 133 222 107 250 617 5.75 < 0.0001 
1418133_at Bcl3 B cell leukemia/lymphoma 3 12051 42 138 136 80 335 461 5.73 0.0006 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 736 720 1048 705 2176 3922 5.56 < 0.0001 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 369 525 720 475 1479 2625 5.53 < 0.0001 
1436861_at Il7 interleukin 7 16196 73 104 123 46 135 240 5.23 0.0001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 549 458 690 506 1472 2594 5.13 < 0.0001 
1418262_at Sykb spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 254 277 421 334 907 1444 4.32 < 0.0001 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 288 345 516 338 740 1354 4.00 < 0.0001 




277 356 517 297 349 1176 3.96 0.0007 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 516 538 551 440 1292 1670 3.79 < 0.0001 
1418110_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 345 428 498 344 752 1281 3.72 < 0.0001 
1450136_at Cd38 CD38 antigen 12494 141 123 131 177 578 644 3.64 < 0.0001 
1433741_at Cd38 CD38 antigen 12494 414 530 662 531 1318 1894 3.57 < 0.0001 
1455656_at Btla B and T lymphocyte associated 20815
4 
218 287 373 282 342 1006 3.57 0.0002 
1449473_s_at Cd40 CD40 antigen 21939 84 45 100 68 145 230 3.39 0.03 
1417597_at Cd28 CD28 antigen 12487 81 91 65 83 114 282 3.39 0.0001 
1425289_a_at Cr2 complement receptor 2 12902 132 161 241 118 135 396 3.35 0.02 
1422003_at Cxcr5 chemokine (C-X-C motif) receptor 5 12145 86 94 179 101 90 326 3.23 0.0003 
1456694_x_at Ptpn6 protein tyrosine phosphatase, non- 15170 449 549 568 367 660 1075 2.93 0.001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
receptor type 6 
1420425_at Prdm1 PR domain containing 1, with ZNF 
domain 
12142 144 169 175 159 193 463 2.92 0.002 
1420404_at Cd86 CD86 antigen 12524 160 152 167 141 232 402 2.85 0.0006 
1452535_at Ighm immunoglobulin heavy constant mu 16019 171 163 236 175 123 494 2.82 0.001 
1421457_a_at Samsn1 SAM domain, SH3 domain and 
nuclear localization signals, 1 
67742 86 122 145 102 185 283 2.76 0.0001 
1419307_at Tnfrsf13c tumor necrosis factor receptor 
superfamily, member 13c 
72049 141 192 284 171 183 472 2.76 0.005 
1453281_at Pik3cd phosphatidylinositol 3-kinase 
catalytic delta polypeptide 
18707 228 201 252 235 350 630 2.69 0.0005 
1423319_at Hhex hematopoietically expressed 
homeobox 
15242 379 409 524 346 644 902 2.61 0.0001 
1460255_at Tnfsf13b tumor necrosis factor (ligand) 
superfamily, member 13b 
24099 340 449 496 381 613 967 2.54 < 0.0001 
1417122_at Vav3 vav 3 oncogene 57257 150 247 205 178 308 447 2.51 0.001 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 234 144 152 186 325 463 2.49 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1439205_at Nfatc2 nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
2 
18019 218 264 301 221 364 538 2.43 0.0006 
1433699_at Tnfaip3 tumor necrosis factor, alpha-induced 
protein 3 
21929 569 683 845 643 1032 1441 2.24 0.0001 
1448600_s_at Vav3 vav 3 oncogene 57257 212 366 305 250 365 542 2.17 0.0006 
1423543_at Swap70 SWA-70 protein 20947 678 412 468 498 490 977 1.96 0.0008 
1460415_a_at Cd40 CD40 antigen 21939 95 54 83 119 130 222 1.88 0.01 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 16164 674 636 504 582 1076 1069 1.84 < 0.0001 
1450829_at Tnfaip3 tumor necrosis factor, alpha-induced 
protein 3 
21929 50 77 119 133 144 239 1.80 0.01 
1424195_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 277 295 192 234 344 410 1.75 0.0001 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 122 162 123 194 244 248 1.28 0.001 
1421818_at Bcl6 B cell leukemia/lymphoma 6 12053 1904 700 919 1243 862 1208 -1.03 0.007 
1448395_at Sfrp1 secreted frizzled-related protein 1 20377 1584 999 626 1162 1758 870 -1.33 0.0003 
1421857_at Adam17 a disintegrin and metallopeptidase 11491 849 443 318 746 452 556 -1.34 0.0003 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
domain 17 
1456429_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
24035
4 
466 236 169 385 312 278 -1.39 0.02 
1431061_s_at Peli1 pellino 1 67245 503 198 269 387 222 270 -1.43 0.002 
1450381_a_at Bcl6 B cell leukemia/lymphoma 6 12053 843 384 390 624 366 434 -1.44 0.0005 
1416594_at Sfrp1 secreted frizzled-related protein 1 20377 476 46 81 379 384 230 -1.64 < 0.0001 
1422102_a_at Stat5b signal transducer and activator of 
transcription 5B 
20851 326 292 265 404 190 213 -1.89 0.002 
1434572_at Hdac9 histone deacetylase 9 79221 1063 818 854 827 532 419 -1.98 0.0001 
1442827_at Tlr4 toll-like receptor 4 21898 413 183 137 320 208 142 -2.26 0.0009 
1421028_a_at Mef2c myocyte enhancer factor 2C 17260 1504 712 697 1362 767 561 -2.43 < 0.0001 
1421027_a_at Mef2c myocyte enhancer factor 2C 17260 2673 1597 972 2514 1694 854 -2.94 < 0.0001 




C) Positive regulation of B cell mediated immunity 
 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1418340_at Fcer1g Fc receptor, IgE, high affinity I, 
gamma polypeptide 
14127 507 690 889 382 2708 5707 14.95 < 0.0001 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 324 357 399 369 1881 3536 9.58 < 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, 
receptor type, C 
19264 486 772 990 642 2454 5106 7.95 < 0.0001 
1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 156 174 234 153 627 1066 6.96 < 0.0001 
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 < 0.0001 
1422122_at Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
14128 140 73 232 93 112 342 3.67 0.02 






D) Positive regulation of B cell activation 
 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 88 124 211 108 189 14621 135.31 < 0.0001 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 49 77 38 34 66 4275 126.80 0.0007 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 82 67 73 51 91 4981 97.95 < 0.0001 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 543 718 1806 648 992 17344 26.75 < 0.0001 
1450297_at Il6 interleukin 6 16193 21 10 57 21 290 523 24.46 0.0001 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 444 654 3608 658 1452 15930 24.20 0.001 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 600 957 1072 623 660 7671 12.32 < 0.0001 
1428787_at Nckap1l NCK associated protein 1 like 10585
5 
130 86 249 159 779 1589 10.00 < 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, 
receptor type, C 
19264 486 772 990 642 2454 5106 7.95 < 0.0001 
1437025_at Cd28 CD28 antigen 12487 44 83 77 36 151 265 7.29 0.02 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 281 418 374 235 769 1613 6.86 0.003 
1418261_at Sykb spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide 
of major histocompatibility complex, 
class II antigen-associated) 
16149 1634 2699 4537 1955 7675 11699 5.98 < 0.0001 
1428786_at Nckap1l NCK associated protein 1 like 10585
5 
283 375 583 364 896 2157 5.92 < 0.0001 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 369 525 720 475 1479 2625 5.53 < 0.0001 
1436861_at Il7 interleukin 7 16196 73 104 123 46 135 240 5.23 0.0001 
1418262_at Sykb spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 < 0.0001 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 288 345 516 338 740 1354 4.00 < 0.0001 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 516 538 551 440 1292 1670 3.79 < 0.0001 
1418110_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 345 428 498 344 752 1281 3.72 < 0.0001 
1450136_at Cd38 CD38 antigen 12494 141 123 131 177 578 644 3.64 < 0.0001 
1433741_at Cd38 CD38 antigen 12494 414 530 662 531 1318 1894 3.57 < 0.0001 
1449473_s_at Cd40 CD40 antigen 21939 84 45 100 68 145 230 3.39 0.03 
1417597_at Cd28 CD28 antigen 12487 81 91 65 83 114 282 3.39 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1420425_at Prdm1 PR domain containing 1, with ZNF 
domain 
12142 144 169 175 159 193 463 2.92 0.002 
1452535_at Ighm immunoglobulin heavy constant mu 16019 171 163 236 175 123 494 2.82 0.001 
1419307_at Tnfrsf13c tumor necrosis factor receptor 
superfamily, member 13c 
72049 141 192 284 171 183 472 2.76 0.005 
1460255_at Tnfsf13b tumor necrosis factor (ligand) 
superfamily, member 13b 
24099 340 449 496 381 613 967 2.54 < 0.0001 
1417122_at Vav3 vav 3 oncogene 57257 150 247 205 178 308 447 2.51 0.001 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 234 144 152 186 325 463 2.49 < 0.0001 
1439205_at Nfatc2 nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
2 
18019 218 264 301 221 364 538 2.43 0.0006 
1448600_s_at Vav3 vav 3 oncogene 57257 212 366 305 250 365 542 2.17 0.0006 
1460415_a_at Cd40 CD40 antigen 21939 95 54 83 119 130 222 1.88 0.01 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 16164 674 636 504 582 1076 1069 1.84 < 0.0001 
1424195_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 277 295 192 234 344 410 1.75 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 122 162 123 194 244 248 1.28 0.001 
1421818_at Bcl6 B cell leukemia/lymphoma 6 12053 1904 700 919 1243 862 1208 -1.03 0.007 
1431061_s_at Peli1 pellino 1 67245 503 198 269 387 222 270 -1.43 0.002 
1450381_a_at Bcl6 B cell leukemia/lymphoma 6 12053 843 384 390 624 366 434 -1.44 0.0005 
1422102_a_at Stat5b signal transducer and activator of 
transcription 5B 
20851 326 292 265 404 190 213 -1.89 0.002 
1442827_at Tlr4 toll-like receptor 4 21898 413 183 137 320 208 142 -2.26 0.0009 
 
E) B cell proliferation 
 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 88 124 211 108 189 14621 135.31 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 49 77 38 34 66 4275 126.80 0.0007 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 82 67 73 51 91 4981 97.95 < 0.0001 
1448576_at Il7r interleukin 7 receptor 16197 9 10 17 21 471 938 45.04 < 0.0001 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 543 718 1806 648 992 17344 26.75 < 0.0001 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 444 654 3608 658 1452 15930 24.20 0.001 
1448575_at Il7r interleukin 7 receptor 16197 106 150 203 136 1187 3130 22.99 < 0.0001 
1423182_at Tnfrsf13b tumor necrosis factor receptor 
superfamily, member 13b 
57916 39 53 123 46 162 647 14.17 < 0.0001 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 600 957 1072 623 660 7671 12.32 < 0.0001 
1428787_at Nckap1l NCK associated protein 1 like 10585
5 
130 86 249 159 779 1589 10.00 < 0.0001 
1418830_at Cd79a CD79A antigen (immunoglobulin-
associated alpha) 
12518 112 143 394 127 150 1235 9.73 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, 
receptor type, C 
19264 486 772 990 642 2454 5106 7.95 < 0.0001 
1422631_at Ahr aryl-hydrocarbon receptor 11622 227 284 231 185 675 1161 6.29 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide 
of major histocompatibility complex, 
class II antigen-associated) 
16149 1634 2699 4537 1955 7675 11699 5.98 < 0.0001 
1428786_at Nckap1l NCK associated protein 1 like 10585
5 
283 375 583 364 896 2157 5.92 < 0.0001 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 736 720 1048 705 2176 3922 5.56 < 0.0001 
1436861_at Il7 interleukin 7 16196 73 104 123 46 135 240 5.23 0.0001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 549 458 690 506 1472 2594 5.13 < 0.0001 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 254 277 421 334 907 1444 4.32 < 0.0001 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 288 345 516 338 740 1354 4.00 < 0.0001 
1418110_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 345 428 498 344 752 1281 3.72 < 0.0001 
1450136_at Cd38 CD38 antigen 12494 141 123 131 177 578 644 3.64 < 0.0001 
1433741_at Cd38 CD38 antigen 12494 414 530 662 531 1318 1894 3.57 < 0.0001 
1455656_at Btla B and T lymphocyte associated 20815
4 
218 287 373 282 342 1006 3.57 0.0002 
1449473_s_at Cd40 CD40 antigen 21939 84 45 100 68 145 230 3.39 0.03 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1420425_at Prdm1 PR domain containing 1, with ZNF 
domain 
12142 144 169 175 159 193 463 2.92 0.002 
1452535_at Ighm immunoglobulin heavy constant mu 16019 171 163 236 175 123 494 2.82 0.001 
1419307_at Tnfrsf13c tumor necrosis factor receptor 
superfamily, member 13c 
72049 141 192 284 171 183 472 2.76 0.005 
1460255_at Tnfsf13b tumor necrosis factor (ligand) 
superfamily, member 13b 
24099 340 449 496 381 613 967 2.54 < 0.0001 
1417122_at Vav3 vav 3 oncogene 57257 150 247 205 178 308 447 2.51 0.001 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 234 144 152 186 325 463 2.49 < 0.0001 
1439205_at Nfatc2 nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
2 
18019 218 264 301 221 364 538 2.43 0.0006 
1448600_s_at Vav3 vav 3 oncogene 57257 212 366 305 250 365 542 2.17 0.0006 
1460415_a_at Cd40 CD40 antigen 21939 95 54 83 119 130 222 1.88 0.01 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 16164 674 636 504 582 1076 1069 1.84 < 0.0001 
1424195_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 277 295 192 234 344 410 1.75 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 122 162 123 194 244 248 1.28 0.001 
1421818_at Bcl6 B cell leukemia/lymphoma 6 12053 1904 700 919 1243 862 1208 -1.03 0.007 
1431061_s_at Peli1 pellino 1 67245 503 198 269 387 222 270 -1.43 0.002 
1450381_a_at Bcl6 B cell leukemia/lymphoma 6 12053 843 384 390 624 366 434 -1.44 0.0005 
1442827_at Tlr4 toll-like receptor 4 21898 413 183 137 320 208 142 -2.26 0.0009 
1421028_a_at Mef2c myocyte enhancer factor 2C 17260 1504 712 697 1362 767 561 -2.43 < 0.0001 
1421027_a_at Mef2c myocyte enhancer factor 2C 17260 2673 1597 972 2514 1694 854 -2.94 < 0.0001 
 
F) B cell differentiation 
 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1460188_at Ptpn6 protein tyrosine phosphatase, non- 15170 37 51 198 46 567 1324 28.96 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
receptor type 6 
1436312_at Ikzf1 IKAROS family zinc finger 1 22778 40 43 212 35 338 948 27.12 < 0.0001 
1425477_x_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 279 361 491 263 1416 3555 13.53 < 0.0001 
1428787_at Nckap1l NCK associated protein 1 like 10585
5 
130 86 249 159 779 1589 10.00 < 0.0001 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 457 616 941 514 2144 5102 9.93 < 0.0001 
1418830_at Cd79a CD79A antigen (immunoglobulin-
associated alpha) 
12518 112 143 394 127 150 1235 9.73 0.0001 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen 
A, beta 1 
14961 780 1005 1459 782 2234 6399 8.19 < 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, 
receptor type, C 
19264 486 772 990 642 2454 5106 7.95 < 0.0001 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 281 418 374 235 769 1613 6.86 0.003 
1418261_at Sykb spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 < 0.0001 
1428786_at Nckap1l NCK associated protein 1 like 10585
5 
283 375 583 364 896 2157 5.92 < 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
1437356_at Gpr183 G protein-coupled receptor 183 32101
9 
103 133 222 107 250 617 5.75 < 0.0001 
1418133_at Bcl3 B cell leukemia/lymphoma 3 12051 42 138 136 80 335 461 5.73 0.0006 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 369 525 720 475 1479 2625 5.53 < 0.0001 
1418262_at Sykb spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 < 0.0001 
1418110_a_at Inpp5d inositol polyphosphate-5-
phosphatase D 
16331 345 428 498 344 752 1281 3.72 < 0.0001 
1456694_x_at Ptpn6 protein tyrosine phosphatase, non-
receptor type 6 
15170 449 549 568 367 660 1075 2.93 0.001 
1420425_at Prdm1 PR domain containing 1, with ZNF 
domain 
12142 144 169 175 159 193 463 2.92 0.002 
1423319_at Hhex hematopoietically expressed 
homeobox 
15242 379 409 524 346 644 902 2.61 0.0001 
1433699_at Tnfaip3 tumor necrosis factor, alpha-induced 
protein 3 
21929 569 683 845 643 1032 1441 2.24 0.0001 
1450829_at Tnfaip3 tumor necrosis factor, alpha-induced 
protein 3 
21929 50 77 119 133 144 239 1.80 0.01 
1424195_a_at Inpp5d inositol polyphosphate-5- 16331 277 295 192 234 344 410 1.75 0.0001 
Affymetrix 


































vs. 6 weeks 
p ANOVA 
phosphatase D 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 122 162 123 194 244 248 1.28 0.001 
1421818_at Bcl6 B cell leukemia/lymphoma 6 12053 1904 700 919 1243 862 1208 -1.03 0.007 
1448395_at Sfrp1 secreted frizzled-related protein 1 20377 1584 999 626 1162 1758 870 -1.33 0.0003 
1421857_at Adam17 A disintegrin and metallopeptidase 
domain 17 
11491 849 443 318 746 452 556 -1.34 0.0003 
1456429_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
24035
4 
466 236 169 385 312 278 -1.39 0.02 
1450381_a_at Bcl6 B cell leukemia/lymphoma 6 12053 843 384 390 624 366 434 -1.44 0.0005 
1416594_at Sfrp1 secreted frizzled-related protein 1 20377 476 46 81 379 384 230 -1.64 < 0.0001 
1422102_a_at Stat5b signal transducer and activator of 
transcription 5B 
20851 326 292 265 404 190 213 -1.89 0.002 
1434572_at Hdac9 histone deacetylase 9 79221 1063 818 854 827 532 419 -1.98 0.0001 
1421306_a_at Hdac9 histone deacetylase 9 79221 305 172 99 215 135 54 -3.94 0.0005 
 
 
A2: Aging-spleen: Differential expression of transcripts coding B cell regulating genes in WT and ApoE-/- spleen (Fig.S1A,B). 
A) B cell mediated immunity 
 
Affymetrix 























78 weeks vs. 
32 weeks 
p ANOVA 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 218 80 161 86 -1.88 0.02 
1451713_a_at Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
14128 1410 900 793 423 -1.88 0.002 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 3058 1497 3033 1566 -1.94 0.0003 
1420577_at Aicda activation-induced cytidine deaminase 11628 307 192 459 160 -2.87 0.002 
 
B) B cell activation 
 
Affymetrix 























78 weeks vs. 
p ANOVA 
32 weeks 
1460187_at Sfrp1 secreted frizzled-related protein 1 20377 486 672 404 963 2.38 0.01 
1426910_at Pawr PRKC, apoptosis, WT1, regulator 114774 353 681 366 841 2.30 0.0002 
1417122_at Vav3 vav 3 oncogene 57257 204 429 211 472 2.24 0.001 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 90 201 144 303 2.10 0.008 
1451737_at Pik3r1 phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) 
18708 687 313 494 295 -1.68 0.005 
1456429_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
240354 2161 986 1831 992 -1.85 0.004 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 218 80 161 86 -1.88 0.02 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 3058 1497 3033 1566 -1.94 0.0003 
1445068_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
240354 1491 612 1058 532 -1.99 0.005 
1425797_a_at Sykb spleen tyrosine kinase 20963 1587 610 1306 598 -2.18 0.001 
1427764_a_at Tcf3 transcription factor 3 21423 882 317 655 286 -2.29 0.0002 





C) Positive regulation of B cell mediated immunity 
 
Affymetrix 























78 weeks vs. 
32 weeks 
p ANOVA 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 218 80 161 86 -1.88 0.02 
1451713_a_at Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
14128 1410 900 793 423 -1.88 0.002 
 
D) Positive regulation of B cell activation 
 
Affymetrix 























78 weeks vs. 
32 weeks 
p ANOVA 
1417122_at Vav3 vav 3 oncogene 57257 204 429 211 472 2.24 0.001 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 90 201 144 303 2.10 0.008 
1440165_at Ptprc protein tyrosine phosphatase, receptor 19264 218 80 161 86 -1.88 0.02 
type, C 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 3058 1497 3033 1566 -1.94 0.0003 
1425797_a_at Sykb spleen tyrosine kinase 20963 1587 610 1306 598 -2.18 0.001 
1427764_a_at Tcf3 transcription factor 3 21423 882 317 655 286 -2.29 0.0002 
 
E) B cell proliferation 
 
Affymetrix 























78 weeks vs. 
32 weeks 
p ANOVA 
1426910_at Pawr PRKC, apoptosis, WT1, regulator 114774 353 681 366 841 2.30 0.0002 
1417122_at Vav3 vav 3 oncogene 57257 204 429 211 472 2.24 0.001 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 90 201 144 303 2.10 0.008 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 218 80 161 86 -1.88 0.02 




F) B cell differentiation 
 
Affymetrix 























78 weeks vs. 
32 weeks 
p ANOVA 
1460187_at Sfrp1 secreted frizzled-related protein 1 20377 486 672 404 963 2.38 0.01 
1451737_at Pik3r1 phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) 
18708 687 313 494 295 -1.68 0.005 
1456429_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
240354 2161 986 1831 992 -1.85 0.004 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 218 80 161 86 -1.88 0.02 
1445068_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
240354 1491 612 1058 532 -1.99 0.005 
1425797_a_at Sykb spleen tyrosine kinase 20963 1587 610 1306 598 -2.18 0.001 





A3: Aging-blood: Differential expression of transcripts coding B cell regulating genes in WT and ApoE-/- blood (Fig.S1C,D). 
A) B cell mediated immunity 
 
Affymetrix 






















78 weeks vs. 
32 weeks 
p ANOVA 
1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 412 423 718 915 1.27 0.01 
1417244_a_at Irf7 interferon regulatory factor 7 54123 1415 1063 2119 2151 1.02 0.01 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 710 61 589 171 -3.44 0.02 
 
B) B cell activation 
 
Affymetrix 






















78 weeks vs. 
32 weeks 
p ANOVA 
1425714_a_at Nfam1 Nfat activating molecule with ITAM motif 
1 
74039 1118 355 1011 1007 -1.00 0.03 
1421140_a_at Foxp1 forkhead box P1 108655 2904 1277 2116 1360 -1.56 0.04 
1438802_at Foxp1 forkhead box P1 108655 1653 740 1582 646 -2.45 0.006 
1445068_at Malt1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
240354 1845 409 1463 558 -2.62 0.01 
1457239_at Sykb spleen tyrosine kinase 20963 183 48 292 86 -3.38 0.04 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 710 61 589 171 -3.44 0.02 
 
C) Positive regulation of B cell mediated immunity 
 
Affymetrix 






















78 weeks vs. 
32 weeks 
p ANOVA 
1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 412 423 718 915 1.27 0.01 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 





D) Positive regulation of B cell activation 
 
Affymetrix 






















78 weeks vs. 
32 weeks 
p ANOVA 
1457239_at Sykb spleen tyrosine kinase 20963 183 48 292 86 -3.38 0.04 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 710 61 589 171 -3.44 0.02 
 
E) B cell differentiation 
 
Affymetrix 






















78 weeks vs. 
32 weeks 
p ANOVA 
1425714_a_at Nfam1 Nfat activating molecule with ITAM motif 
1 
74039 1118 355 1011 1007 -1.00 0.03 
1421140_a_at Foxp1 forkhead box P1 108655 2904 1277 2116 1360 -1.56 0.04 
1438802_at Foxp1 forkhead box P1 108655 1653 740 1582 646 -2.45 0.006 
1445068_at Malt1 mucosa associated lymphoid tissue 240354 1845 409 1463 558 -2.62 0.01 
lymphoma translocation gene 1 
1457239_at Sykb spleen tyrosine kinase 20963 183 48 292 86 -3.38 0.04 
1440165_at Ptprc protein tyrosine phosphatase, receptor 
type, C 
19264 710 61 589 171 -3.44 0.02 
 
B. Transcript atlas of WT adventitia, ApoE-/- adventitia without plaque, plaque, and ATLOs reveal the territoriality of B cell immunity in 
the diseased aorta (Fig.2).  
B1: Adventitia cluster: Differential expression of transcripts coding for B cell-regulating genes in WT and ApoE-/- aorta adventitia:  
A) B cell mediated immunity 
Affymetrix 






















1425324_x_at Ighm immunoglobulin heavy constant mu 16019 317 284 7656 26.93 0.04 
1427869_at Ighm immunoglobulin heavy constant mu 16019 11 12 246 20.65 0.01 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 1315 816 10203 12.50 0.05 
1425477_x_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 235 269 2613 9.70 0.0004 
Affymetrix 






















1460188_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 150 105 926 8.78 0.004 
1424302_at Lilrb3 leukocyte immunoglobulin-like receptor, subfamily B 
(with TM and ITIM domains), member 3 
18733 102 184 1245 6.77 < 0.0001 
1422124_a_at Ptprc protein tyrosine phosphatase, receptor type, C 19264 941 1071 6773 6.32 0.0004 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 435 582 3528 6.06 0.0008 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 252 390 2245 5.75 < 0.0001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 282 355 1782 5.01 0.0002 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 695 1072 5035 4.70 < 0.0001 
1422527_at H2-DMa histocompatibility 2, class II, locus DMa 14998 297 361 1653 4.57 0.0002 
1417597_at Cd28 CD28 antigen 12487 72 98 446 4.55 0.002 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 59 64 284 4.42 0.002 
1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 120 176 735 4.18 0.0004 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
16149 3626 4458 18504 4.15 0.0002 
Affymetrix 






















1423543_at Swap70 SWA-70 protein 20947 199 158 655 4.14 0.002 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 1634 1981 7773 3.92 0.0002 
1435476_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 829 971 3572 3.68 < 0.0001 
1449473_s_at Cd40 CD40 antigen 21939 86 105 376 3.58 0.0003 
1418133_at Bcl3 B cell leukemia/lymphoma 3 12051 96 165 570 3.45 0.001 
1434366_x_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 1731 2698 8974 3.33 0.0003 
1417063_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 903 1570 5054 3.22 0.0002 
1418340_at Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 14127 435 682 2149 3.15 0.0004 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 8628 9893 30659 3.10 0.03 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 431 693 1955 2.82 0.001 
1417381_at C1qa complement component 1, q subcomponent, alpha 
polypeptide 
12259 1022 1724 4626 2.68 0.002 
1437726_x_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 2201 3878 10107 2.61 0.0003 
Affymetrix 






















1418021_at C4b complement component 4B (Childo blood group) 12268 3136 4259 10968 2.58 < 0.0001 
1417009_at C1ra complement component 1, r subcomponent A 50909 569 804 2035 2.53 0.0003 
1423954_at C3 complement component 3 12266 5736 7932 18139 2.29 < 0.0001 
1422847_a_at Prkcd protein kinase C, delta 18753 496 489 1036 2.12 0.0005 
1424041_s_at C1s complement component 1, s subcomponent 50908 1333 1738 3663 2.11 0.0009 
1419272_at Myd88 myeloid differentiation primary response gene 88 17874 711 761 1601 2.10 0.0002 
1416625_at Serping1 serine (or cysteine) peptidase inhibitor, clade G, 
member 1 
12258 5258 7199 13937 1.94 0.006 
1416051_at C2 complement component 2 (within H-2S) 12263 765 858 1652 1.92 0.009 
1456694_x_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 414 568 1084 1.91 0.004 
1418110_a_at Inpp5d inositol polyphosphate-5-phosphatase D 16331 362 433 821 1.90 0.002 
1419212_at Icosl icos ligand 50723 271 376 592 1.57 0.004 
1421775_at Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide 14125 52 202 134 -1.51 0.02 
1424456_at Pvrl2 poliovirus receptor-related 2 19294 177 287 138 -2.07 0.02 
 
B) B cell activation 
 
Affymetrix 






















1425324_x_at Ighm immunoglobulin heavy constant mu 16019 317 284 7656 26.93 0.04 
1427869_at Ighm immunoglobulin heavy constant mu 16019 11 12 246 20.65 0.01 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 1315 816 10203 12.50 0.05 
1448576_at Il7r interleukin 7 receptor 16197 11 24 270 11.10 0.02 
1425477_x_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 235 269 2613 9.70 0.0004 
1448575_at Il7r interleukin 7 receptor 16197 140 168 1546 9.22 0.0002 
1460188_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 150 105 926 8.78 0.004 
1418830_at Cd79a CD79A antigen (immunoglobulin-associated alpha) 12518 229 158 1276 8.09 0.003 
1423182_at Tnfrsf13b tumor necrosis factor receptor superfamily, member 
13b 
57916 143 130 959 7.38 0.002 
1419406_a_at Bcl11a B cell CLL/lymphoma 11A (zinc finger protein) 14025 94 42 306 7.25 0.03 
1423226_at Ms4a1 membrane-spanning 4-domains, subfamily A, 
member 1 
12482 406 260 1842 7.08 0.04 
Affymetrix 






















1422124_a_at Ptprc protein tyrosine phosphatase, receptor type, C 19264 941 1071 6773 6.32 0.0004 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 435 582 3528 6.06 0.0008 
1416034_at Cd24a CD24a antigen 12484 721 222 1324 5.95 0.02 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 252 390 2245 5.75 < 0.0001 
1417976_at Ada adenosine deaminase 11486 68 66 354 5.36 0.008 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 215 186 950 5.10 0.01 
1451780_at Blnk B cell linker 17060 363 356 1796 5.04 0.001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 282 355 1782 5.01 0.0002 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 695 1072 5035 4.70 < 0.0001 
1417597_at Cd28 CD28 antigen 12487 72 98 446 4.55 0.002 
1419538_at Flt3 FMS-like tyrosine kinase 3 14255 71 52 237 4.52 0.02 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 665 756 3396 4.49 0.001 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 59 64 284 4.42 0.002 
Affymetrix 






















1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 52 61 268 4.40 0.0009 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 177 239 1045 4.38 0.0001 
1448182_a_at Cd24a CD24a antigen 12484 2648 898 3859 4.30 0.004 
1428787_at Nckap1l NCK associated protein 1 like 105855 151 163 702 4.30 0.0007 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 401 329 1410 4.28 0.003 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
16149 3626 4458 18504 4.15 0.0002 
1423543_at Swap70 SWA-70 protein 20947 199 158 655 4.14 0.002 
1418261_at Sykb spleen tyrosine kinase 20963 307 392 1601 4.08 0.0002 
1437502_x_at Cd24a CD24a antigen 12484 1303 540 2187 4.05 0.002 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 1634 1981 7773 3.92 0.0002 
1435476_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 829 971 3572 3.68 < 0.0001 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 126 110 402 3.66 0.002 
Affymetrix 






















1449473_s_at Cd40 CD40 antigen 21939 86 105 376 3.58 0.0003 
1418133_at Bcl3 B cell leukemia/lymphoma 3 12051 96 165 570 3.45 0.001 
1418262_at Sykb spleen tyrosine kinase 20963 108 118 401 3.39 0.002 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 394 423 1420 3.36 0.0004 
1428786_at Nckap1l NCK associated protein 1 like 105855 289 404 1335 3.31 < 0.0001 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 16164 116 144 457 3.17 0.0008 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 8628 9893 30659 3.10 0.03 
1422003_at Cxcr5 chemokine (C-X-C motif) receptor 5 12145 77 95 294 3.08 0.02 
1420351_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 
4 
22163 292 232 710 3.06 0.002 
1453281_at Pik3cd phosphatidylinositol 3-kinase catalytic delta 
polypeptide 
18707 161 186 565 3.04 < 0.0001 
1460419_a_at Prkcb protein kinase C, beta 18751 603 528 1599 3.03 0.0003 
1426926_at Plcg2 phospholipase C, gamma 2 234779 494 418 1220 2.92 0.0002 
1433741_at Cd38 CD38 antigen 12494 499 589 1580 2.68 0.0002 
Affymetrix 






















1420404_at Cd86 CD86 antigen 12524 129 167 422 2.53 0.0002 
1423478_at Prkcb protein kinase C, beta 18751 139 171 414 2.42 0.007 
1421141_a_at Foxp1 forkhead box P1 108655 93 86 197 2.30 0.02 
1421858_at Adam17 a disintegrin and metallopeptidase domain 17 11491 429 477 1039 2.18 0.0003 
1421205_at Atm ataxia telangiectasia mutated homolog (human) 11920 218 150 319 2.13 0.03 
1422847_a_at Prkcd protein kinase C, delta 18753 496 489 1036 2.12 0.0005 
1456694_x_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 414 568 1084 1.91 0.004 
1418110_a_at Inpp5d inositol polyphosphate-5-phosphatase D 16331 362 433 821 1.90 0.002 
1435176_a_at Id2 inhibitor of DNA binding 2 15902 1205 1571 2573 1.64 0.006 
1419212_at Icosl icos ligand 50723 271 376 592 1.57 0.004 





























1425324_x_at Ighm immunoglobulin heavy constant mu 16019 317 284 7656 26.93 0.04 
1427869_at Ighm immunoglobulin heavy constant mu 16019 11 12 246 20.65 0.01 
1424305_at Igj immunoglobulin joining chain 16069 6602 4731 21748 4.60 0.002 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 8628 9893 30659 3.10 0.03 
 
D) Positive regulation of B cell mediated immunity 
 
Affymetrix 






















1422124_a_at Ptprc protein tyrosine phosphatase, receptor type, C 19264 941 1071 6773 6.32 0.0004 
1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 120 176 735 4.18 0.0004 
1418340_at Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 14127 435 682 2149 3.15 0.0004 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 431 693 1955 2.82 0.001 
1423954_at C3 complement component 3 12266 5736 7932 18139 2.29 < 0.0001 
1421775_at Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide 14125 52 202 134 -1.51 0.02 
1424456_at Pvrl2 poliovirus receptor-related 2 19294 177 287 138 -2.07 0.02 
 
E) Positive regulation of B cell activation 
 
Affymetrix 






















1425324_x_at Ighm immunoglobulin heavy constant mu 16019 317 284 7656 26.93 0.04 
1427869_at Ighm immunoglobulin heavy constant mu 16019 11 12 246 20.65 0.01 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 1315 816 10203 12.50 0.05 
1422124_a_at Ptprc protein tyrosine phosphatase, receptor type, C 19264 941 1071 6773 6.32 0.0004 
1417976_at Ada adenosine deaminase 11486 68 66 354 5.36 0.008 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 215 186 950 5.10 0.01 
1417597_at Cd28 CD28 antigen 12487 72 98 446 4.55 0.002 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 665 756 3396 4.49 0.001 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 59 64 284 4.42 0.002 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 52 61 268 4.40 0.0009 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 177 239 1045 4.38 0.0001 
1428787_at Nckap1l NCK associated protein 1 like 105855 151 163 702 4.30 0.0007 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 401 329 1410 4.28 0.003 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
16149 3626 4458 18504 4.15 0.0002 
1418261_at Sykb spleen tyrosine kinase 20963 307 392 1601 4.08 0.0002 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 126 110 402 3.66 0.002 
1449473_s_at Cd40 CD40 antigen 21939 86 105 376 3.58 0.0003 
1418262_at Sykb spleen tyrosine kinase 20963 108 118 401 3.39 0.002 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 394 423 1420 3.36 0.0004 
1428786_at Nckap1l NCK associated protein 1 like 105855 289 404 1335 3.31 < 0.0001 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 16164 116 144 457 3.17 0.0008 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 8628 9893 30659 3.10 0.03 
1420351_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 
4 
22163 292 232 710 3.06 0.002 
1433741_at Cd38 CD38 antigen 12494 499 589 1580 2.68 0.0002 
1418110_a_at Inpp5d inositol polyphosphate-5-phosphatase D 16331 362 433 821 1.90 0.002 
 
F) B cell proliferation 
 
Affymetrix 






















1425324_x_at Ighm immunoglobulin heavy constant mu 16019 317 284 7656 26.93 0.04 
1427869_at Ighm immunoglobulin heavy constant mu 16019 11 12 246 20.65 0.01 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 1315 816 10203 12.50 0.05 
1448576_at Il7r interleukin 7 receptor 16197 11 24 270 11.10 0.02 
1448575_at Il7r interleukin 7 receptor 16197 140 168 1546 9.22 0.0002 
1418830_at Cd79a CD79A antigen (immunoglobulin-associated alpha) 12518 229 158 1276 8.09 0.003 
1423182_at Tnfrsf13b tumor necrosis factor receptor superfamily, member 
13b 
57916 143 130 959 7.38 0.002 
1422124_a_at Ptprc protein tyrosine phosphatase, receptor type, C 19264 941 1071 6773 6.32 0.0004 
1416034_at Cd24a CD24a antigen 12484 721 222 1324 5.95 0.02 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 252 390 2245 5.75 < 0.0001 
1417976_at Ada adenosine deaminase 11486 68 66 354 5.36 0.008 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 215 186 950 5.10 0.01 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 282 355 1782 5.01 0.0002 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 695 1072 5035 4.70 < 0.0001 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 59 64 284 4.42 0.002 
1427164_at Il13ra1 interleukin 13 receptor, alpha 1 16164 52 61 268 4.40 0.0009 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 177 239 1045 4.38 0.0001 
1448182_a_at Cd24a CD24a antigen 12484 2648 898 3859 4.30 0.004 
1428787_at Nckap1l NCK associated protein 1 like 105855 151 163 702 4.30 0.0007 
1425519_a_at Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
16149 3626 4458 18504 4.15 0.0002 
1437502_x_at Cd24a CD24a antigen 12484 1303 540 2187 4.05 0.002 
1435476_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 829 971 3572 3.68 < 0.0001 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 126 110 402 3.66 0.002 
1449473_s_at Cd40 CD40 antigen 21939 86 105 376 3.58 0.0003 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 394 423 1420 3.36 0.0004 
1428786_at Nckap1l NCK associated protein 1 like 105855 289 404 1335 3.31 < 0.0001 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 16164 116 144 457 3.17 0.0008 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 8628 9893 30659 3.10 0.03 
1420351_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 
4 
22163 292 232 710 3.06 0.002 
1433741_at Cd38 CD38 antigen 12494 499 589 1580 2.68 0.0002 
1421205_at Atm ataxia telangiectasia mutated homolog (human) 11920 218 150 319 2.13 0.03 
1422847_a_at Prkcd protein kinase C, delta 18753 496 489 1036 2.12 0.0005 
1418110_a_at Inpp5d inositol polyphosphate-5-phosphatase D 16331 362 433 821 1.90 0.002 
 
G) B cell differentiation 
 
Affymetrix 






















1425477_x_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 235 269 2613 9.70 0.0004 
1460188_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 150 105 926 8.78 0.004 
1418830_at Cd79a CD79A antigen (immunoglobulin-associated alpha) 12518 229 158 1276 8.09 0.003 
1419406_a_at Bcl11a B cell CLL/lymphoma 11A (zinc finger protein) 14025 94 42 306 7.25 0.03 
1422124_a_at Ptprc protein tyrosine phosphatase, receptor type, C 19264 941 1071 6773 6.32 0.0004 
1451721_a_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 435 582 3528 6.06 0.0008 
1416034_at Cd24a CD24a antigen 12484 721 222 1324 5.95 0.02 
1417976_at Ada adenosine deaminase 11486 68 66 354 5.36 0.008 
1419538_at Flt3 FMS-like tyrosine kinase 3 14255 71 52 237 4.52 0.02 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 665 756 3396 4.49 0.001 
1437270_a_at Clcf1 cardiotrophin-like cytokine factor 1 56708 59 64 284 4.42 0.002 
1448182_a_at Cd24a CD24a antigen 12484 2648 898 3859 4.30 0.004 
1428787_at Nckap1l NCK associated protein 1 like 105855 151 163 702 4.30 0.0007 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 401 329 1410 4.28 0.003 
1418261_at Sykb spleen tyrosine kinase 20963 307 392 1601 4.08 0.0002 
1437502_x_at Cd24a CD24a antigen 12484 1303 540 2187 4.05 0.002 
1450648_s_at H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 1634 1981 7773 3.92 0.0002 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 126 110 402 3.66 0.002 
1418133_at Bcl3 B cell leukemia/lymphoma 3 12051 96 165 570 3.45 0.001 
1418262_at Sykb spleen tyrosine kinase 20963 108 118 401 3.39 0.002 
1428786_at Nckap1l NCK associated protein 1 like 105855 289 404 1335 3.31 < 0.0001 
1426926_at Plcg2 phospholipase C, gamma 2 234779 494 418 1220 2.92 0.0002 
1421141_a_at Foxp1 forkhead box P1 108655 93 86 197 2.30 0.02 
1421858_at Adam17 a disintegrin and metallopeptidase domain 17 11491 429 477 1039 2.18 0.0003 
1421205_at Atm ataxia telangiectasia mutated homolog (human) 11920 218 150 319 2.13 0.03 
1456694_x_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 414 568 1084 1.91 0.004 
1418110_a_at Inpp5d inositol polyphosphate-5-phosphatase D 16331 362 433 821 1.90 0.002 
1435176_a_at Id2 inhibitor of DNA binding 2 15902 1205 1571 2573 1.64 0.006 
1421999_at Tshr thyroid stimulating hormone receptor 22095 213 278 122 -2.28 0.005 
 
B2: Plaque-ATLO cluster: Differential expression of transcripts coding for B cell-regulating genes in WT and ApoE-/- aorta ATLO-plaque: 
 
A) B cell mediated immunity 
 
Affymetrix 














vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 139 9012 64.79 0.009 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 184 7656 41.51 0.01 
1427869_at Ighm immunoglobulin heavy constant mu 16019 6 246 40.05 0.01 
1416051_at C2 complement component 2 (within H-2S) 12263 68 1652 24.25 0.02 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 610 10203 16.71 0.01 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 2675 30659 11.46 0.009 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 1098 10938 9.96 0.04 
1460242_at Cd55 CD55 antigen 13136 56 321 5.75 0.01 
1423954_at C3 complement component 3 12266 3412 18139 5.32 0.002 
1416625_at Serping1 serine (or cysteine) peptidase inhibitor, clade G, 
member 1 
12258 2789 13937 5.00 0.002 
1418762_at Cd55 CD55 antigen 13136 78 324 4.13 0.009 
1418021_at C4b complement component 4B (Childo blood group) 12268 2810 10968 3.90 0.01 
1449473_s_at Cd40 CD40 antigen 21939 134 376 2.80 0.008 
1419212_at Icosl icos ligand 50723 233 592 2.54 0.003 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 9121 21660 2.37 0.02 
1424041_s_at C1s complement component 1, s subcomponent 50908 1558 3663 2.35 0.003 
1417009_at C1ra complement component 1, r subcomponent A 50909 923 2035 2.20 0.009 
1434366_x_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 19394 8974 -2.16 0.03 
1417063_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 11615 5054 -2.30 0.02 
1417381_at C1qa complement component 1, q subcomponent, alpha 
polypeptide 
12259 11634 4626 -2.51 0.02 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 5147 1955 -2.63 0.003 
1418340_at Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 14127 6206 2149 -2.89 0.003 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 552 189 -2.91 0.04 
 
B) B cell activation 
 
Affymetrix 














vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 139 9012 64.79 0.009 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 184 7656 41.51 0.01 
1427869_at Ighm immunoglobulin heavy constant mu 16019 6 246 40.05 0.01 
1450912_at Ms4a1 membrane-spanning 4-domains, subfamily A, 
member 1 
12482 52 1147 22.21 0.009 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 610 10203 16.71 0.01 
1423226_at Ms4a1 membrane-spanning 4-domains, subfamily A, 
member 1 
12482 120 1842 15.41 0.01 
1418830_at Cd79a CD79A antigen (immunoglobulin-associated alpha) 12518 92 1276 13.85 0.002 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 2675 30659 11.46 0.009 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 1098 10938 9.96 0.04 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 107 950 8.92 0.005 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 182 1045 5.74 0.02 
1422003_at Cxcr5 chemokine (C-X-C motif) receptor 5 12145 52 294 5.68 0.01 
1425289_a_at Cr2 complement receptor 2 12902 86 394 4.58 0.03 
1437502_x_at Cd24a CD24a antigen 12484 521 2187 4.19 0.005 
1448182_a_at Cd24a CD24a antigen 12484 932 3859 4.14 0.009 
1423182_at Tnfrsf13b tumor necrosis factor receptor superfamily, member 
13b 
57916 246 959 3.89 0.01 
1417976_at Ada adenosine deaminase 11486 104 354 3.41 0.04 
1449473_s_at Cd40 CD40 antigen 21939 134 376 2.80 0.008 
1420351_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 
4 
22163 267 710 2.66 0.005 
1419212_at Icosl icos ligand 50723 233 592 2.54 0.003 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 9121 21660 2.37 0.02 
1426297_at Tcf3 transcription factor 3 21423 205 444 2.16 0.03 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 1630 3396 2.08 0.04 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 201 402 2.00 0.03 
1418163_at Tlr4 toll-like receptor 4 21898 485 242 -2.00 0.04 
1417122_at Vav3 vav 3 oncogene 57257 429 196 -2.19 0.006 
1426910_at Pawr PRKC, apoptosis, WT1, regulator 114774 1193 495 -2.41 0.01 
1448575_at Il7r interleukin 7 receptor 16197 3839 1546 -2.48 0.01 
1426169_a_at Lat2 linker for activation of T cells family, member 2 56743 534 200 -2.67 0.007 
1418162_at Tlr4 toll-like receptor 4 21898 637 232 -2.74 0.003 
1450136_at Cd38 CD38 antigen 12494 432 153 -2.82 0.04 
1422537_a_at Id2 inhibitor of DNA binding 2 15902 1227 433 -2.83 0.002 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 552 189 -2.91 0.04 



















vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 139 9012 64.79 0.009 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 184 7656 41.51 0.01 
1427869_at Ighm immunoglobulin heavy constant mu 16019 6 246 40.05 0.01 
1424305_at Igj immunoglobulin joining chain 16069 1300 21748 16.73 0.003 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 2675 30659 11.46 0.009 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 1098 10938 9.96 0.04 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 9121 21660 2.37 0.02 
 
D) Positive regulation of B cell mediated immunity 
 
Affymetrix 














vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1423954_at C3 complement component 3 12266 3412 18139 5.32 0.002 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 5147 1955 -2.63 0.003 







E) Positive regulation of B cell activation 
 
Affymetrix 














vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 139 9012 64.79 0.009 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 184 7656 41.51 0.01 
1427869_at Ighm immunoglobulin heavy constant mu 16019 6 246 40.05 0.01 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 610 10203 16.71 0.01 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 2675 30659 11.46 0.009 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 1098 10938 9.96 0.04 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 107 950 8.92 0.005 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 182 1045 5.74 0.02 
1417976_at Ada adenosine deaminase 11486 104 354 3.41 0.04 
1449473_s_at Cd40 CD40 antigen 21939 134 376 2.80 0.008 
1420351_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 
4 
22163 267 710 2.66 0.005 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 9121 21660 2.37 0.02 
1426297_at Tcf3 transcription factor 3 21423 205 444 2.16 0.03 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 1630 3396 2.08 0.04 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 201 402 2.00 0.03 
1418163_at Tlr4 toll-like receptor 4 21898 485 242 -2.00 0.04 
1417122_at Vav3 vav 3 oncogene 57257 429 196 -2.19 0.006 
1418162_at Tlr4 toll-like receptor 4 21898 637 232 -2.74 0.003 
1450136_at Cd38 CD38 antigen 12494 432 153 -2.82 0.04 
1420653_at Tgfb1 transforming groWTh factor, beta 1 21803 552 189 -2.91 0.04 
 
F) B cell proliferation 
 
Affymetrix 














vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1427756_x_at Ighm immunoglobulin heavy constant mu 16019 139 9012 64.79 0.009 
1425324_x_at Ighm immunoglobulin heavy constant mu 16019 184 7656 41.51 0.01 
1427869_at Ighm immunoglobulin heavy constant mu 16019 6 246 40.05 0.01 
1427870_x_at Ighm immunoglobulin heavy constant mu 16019 610 10203 16.71 0.01 
1418830_at Cd79a CD79A antigen (immunoglobulin-associated alpha) 12518 92 1276 13.85 0.002 
1427329_a_at Ighm immunoglobulin heavy constant mu 16019 2675 30659 11.46 0.009 
1425385_a_at Ighm immunoglobulin heavy constant mu 16019 1098 10938 9.96 0.04 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 107 950 8.92 0.005 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 182 1045 5.74 0.02 
1437502_x_at Cd24a CD24a antigen 12484 521 2187 4.19 0.005 
1448182_a_at Cd24a CD24a antigen 12484 932 3859 4.14 0.009 
1423182_at Tnfrsf13b tumor necrosis factor receptor superfamily, member 
13b 
57916 246 959 3.89 0.01 
1417976_at Ada adenosine deaminase 11486 104 354 3.41 0.04 
1449473_s_at Cd40 CD40 antigen 21939 134 376 2.80 0.008 
1420351_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 
4 
22163 267 710 2.66 0.005 
1427351_s_at Ighm immunoglobulin heavy constant mu 16019 9121 21660 2.37 0.02 
1426297_at Tcf3 transcription factor 3 21423 205 444 2.16 0.03 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 201 402 2.00 0.03 
1418163_at Tlr4 toll-like receptor 4 21898 485 242 -2.00 0.04 
1417122_at Vav3 vav 3 oncogene 57257 429 196 -2.19 0.006 
1426910_at Pawr PRKC, apoptosis, WT1, regulator 114774 1193 495 -2.41 0.01 
1448575_at Il7r interleukin 7 receptor 16197 3839 1546 -2.48 0.01 
1418162_at Tlr4 toll-like receptor 4 21898 637 232 -2.74 0.003 
1450136_at Cd38 CD38 antigen 12494 432 153 -2.82 0.04 
1448576_at Il7r interleukin 7 receptor 16197 977 270 -3.62 0.01 
 
G) B cell differentiation 
 
Affymetrix 














vs.  ApoE-/- 
plaque 
p T-test of 
ApoE-/- ATLO 
vs.  ApoE-/- 
plaque 
1418830_at Cd79a CD79A antigen (immunoglobulin-associated alpha) 12518 92 1276 13.85 0.002 
1437502_x_at Cd24a CD24a antigen 12484 521 2187 4.19 0.005 
1448182_a_at Cd24a CD24a antigen 12484 932 3859 4.14 0.009 
1417976_at Ada adenosine deaminase 11486 104 354 3.41 0.04 
1426297_at Tcf3 transcription factor 3 21423 205 444 2.16 0.03 
1416295_a_at Il2rg interleukin 2 receptor, gamma chain 16186 1630 3396 2.08 0.04 
1420425_at Prdm1 PR domain containing 1, with ZNF domain 12142 201 402 2.00 0.03 
1422537_a_at Id2 inhibitor of DNA binding 2 15902 1227 433 -2.83 0.002 
 
B3: Lymph node cluster: Differential expression of transcripts coding for B cell-regulating genes in WT and ApoE-/- renal lymph nodes 
(Fig.S2): 
 
A) B cell mediated immunity 
 
Affymetrix 



















1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 140 111 735 6.60 0.001 
1434366_x_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 2768 1852 8974 4.85 0.02 
1437726_x_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 3374 2557 10107 3.95 0.01 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 463 499 1955 3.92 0.0006 
1416625_at Serping1 serine (or cysteine) peptidase inhibitor, clade G, 
member 1 
12258 3642 3561 13937 3.91 0.002 
1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 714 649 2245 3.46 0.0009 
1417063_at C1qb complement component 1, q subcomponent, beta 
polypeptide 
12260 2116 1530 5054 3.30 0.008 
1416051_at C2 complement component 2 (within H-2S) 12263 560 648 1652 2.55 0.001 
1417381_at C1qa complement component 1, q subcomponent, alpha 12259 2837 1821 4626 2.54 0.02 
polypeptide 
1435476_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 1530 1454 3572 2.46 0.001 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 2049 2053 5035 2.45 0.001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 667 736 1782 2.42 0.01 
1418021_at C4b complement component 4B (Childo blood group) 12268 4111 4530 10968 2.42 0.002 
1424302_at Lilrb3 leukocyte immunoglobulin-like receptor, subfamily B 
(with TM and ITIM domains), member 3 
18733 549 532 1245 2.34 0.01 
1417009_at C1ra complement component 1, r subcomponent A 50909 827 1029 2035 1.98 0.007 
1437271_at Clcf1 cardiotrophin-like cytokine factor 1 56708 295 238 128 -1.85 0.02 
1416915_at Msh6 muts homolog 6 (E. coli) 17688 623 569 268 -2.12 0.008 
1449361_at Tbx21 T-box 21 57765 403 359 160 -2.24 0.005 
1418026_at Exo1 exonuclease 1 26909 185 148 63 -2.35 0.03 
1449508_at Il27ra interleukin 27 receptor, alpha 50931 619 615 255 -2.41 0.002 
1420353_at Lta lymphotoxin A 16992 348 282 115 -2.45 0.02 
1460188_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 2532 2309 926 -2.49 0.02 
1460415_a_at Cd40 CD40 antigen 21939 701 556 212 -2.62 0.007 
1423543_at Swap70 SWA-70 protein 20947 2012 1857 655 -2.84 0.01 
1417597_at Cd28 CD28 antigen 12487 1260 1540 446 -3.45 0.003 
1460242_at Cd55 CD55 antigen 13136 1161 1111 321 -3.46 0.02 
1418762_at Cd55 CD55 antigen 13136 1018 1179 324 -3.63 0.005 
1420577_at Aicda activation-induced cytidine deaminase 11628 304 249 68 -3.66 0.03 
1437025_at Cd28 CD28 antigen 12487 806 829 196 -4.23 0.0008 
 
B) B cell activation 
 
Affymetrix 



















1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 714 649 2245 3.46 0.0009 
1435476_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 1530 1454 3572 2.46 0.001 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 2049 2053 5035 2.45 0.001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 667 736 1782 2.42 0.01 
1424638_at Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 12575 398 384 860 2.24 0.05 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 453 470 1045 2.22 0.002 
1434694_at Lrrc8a leucine rich repeat containing 8A 241296 456 450 987 2.20 0.005 
1449839_at Casp3 caspase 3 12367 1413 1148 666 -1.72 0.01 
1437271_at Clcf1 cardiotrophin-like cytokine factor 1 56708 295 238 128 -1.85 0.02 
Affymetrix 



















1426297_at Tcf3 transcription factor 3 21423 968 856 444 -1.93 0.004 
1460419_a_at Prkcb protein kinase C, beta 18751 3332 3178 1599 -1.99 0.005 
1420404_at Cd86 CD86 antigen 12524 784 853 422 -2.02 0.002 
1417372_a_at Peli1 pellino 1 67245 2397 2213 1076 -2.06 0.004 
1423478_at Prkcb protein kinase C, beta 18751 914 856 414 -2.07 0.02 
1416915_at Msh6 mutS homolog 6 (E. coli) 17688 623 569 268 -2.12 0.008 
1453281_at Pik3cd phosphatidylinositol 3-kinase catalytic delta 
polypeptide 
18707 1159 1199 565 -2.12 0.002 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 3122 3033 1420 -2.14 0.002 
1416335_at Mif macrophage migration inhibitory factor 17319 4803 4861 2252 -2.16 0.005 
1421142_s_at Foxp1 forkhead box P1 108655 738 723 333 -2.17 0.003 
1421205_at Atm ataxia telangiectasia mutated homolog (human) 11920 682 707 319 -2.22 0.01 
1449361_at Tbx21 T-box 21 57765 403 359 160 -2.24 0.005 
1455242_at Foxp1 forkhead box P1 108655 1928 2227 986 -2.26 0.03 
1451507_at Mef2c myocyte enhancer factor 2C 17260 645 583 255 -2.29 0.05 
Affymetrix 



















1448575_at Il7r interleukin 7 receptor 16197 2453 3546 1546 -2.29 0.003 
1418026_at Exo1 exonuclease 1 26909 185 148 63 -2.35 0.03 
1417371_at Peli1 pellino 1 67245 1567 1680 705 -2.38 0.001 
1449508_at Il27ra interleukin 27 receptor, alpha 50931 619 615 255 -2.41 0.002 
1460188_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 2532 2309 926 -2.49 0.02 
1460415_a_at Cd40 CD40 antigen 21939 701 556 212 -2.62 0.007 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 3033 2499 950 -2.63 0.01 
1419406_a_at Bcl11a B cell CLL/lymphoma 11A (zinc finger protein) 14025 883 809 306 -2.64 0.03 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 3396 3793 1410 -2.69 0.003 
1423543_at Swap70 SWA-70 protein 20947 2012 1857 655 -2.84 0.01 
1436861_at Il7 interleukin 7 16196 359 369 129 -2.86 0.006 
1421028_a_at Mef2c myocyte enhancer factor 2C 17260 691 763 262 -2.92 0.02 
1421141_a_at Foxp1 forkhead box P1 108655 487 581 197 -2.94 0.007 
1419334_at Ctla4 cytotoxic T-lymphocyte-associated protein 4 12477 488 472 147 -3.21 0.002 
Affymetrix 



















1448576_at Il7r interleukin 7 receptor 16197 533 878 270 -3.25 0.02 
1422003_at Cxcr5 chemokine (C-X-C motif) receptor 5 12145 1241 986 294 -3.36 0.007 
1450829_at Tnfaip3 tumor necrosis factor, alpha-induced protein 3 21929 147 218 65 -3.38 0.03 
1449858_at Cd86 CD86 antigen 12524 396 507 149 -3.40 0.009 
1417597_at Cd28 CD28 antigen 12487 1260 1540 446 -3.45 0.003 
1452389_at Cd27 CD27 antigen 21940 444 489 138 -3.53 0.005 
1450912_at Ms4a1 membrane-spanning 4-domains, subfamily A, 
member 1 
12482 4855 4060 1147 -3.54 0.04 
1420577_at Aicda activation-induced cytidine deaminase 11628 304 249 68 -3.66 0.03 
1437025_at Cd28 CD28 antigen 12487 806 829 196 -4.23 0.0008 
1421457_a_at Samsn1 SAM domain, SH3 domain and nuclear localization 
signals, 1 
67742 808 969 225 -4.30 0.004 
1423226_at Ms4a1 membrane-spanning 4-domains, subfamily A, 
member 1 
12482 8776 7974 1842 -4.33 0.03 
1422992_s_at Pik3cd phosphatidylinositol 3-kinase catalytic delta 
polypeptide 
18707 250 285 48 -5.95 0.02 
1425289_a_at Cr2 complement receptor 2 12902 1524 2577 394 -6.54 0.02 
 C) Positive regulation of B cell mediated immunity 
 
Affymetrix 



















1417876_at Fcgr1 Fc receptor, IgG, high affinity I 14129 140 111 735 6.60 0.001 
1448620_at Fcgr3 Fc receptor, IgG, low affinity III 14131 463 499 1955 3.92 0.0006 
1420353_at Lta lymphotoxin A 16992 348 282 115 -2.45 0.02 
 
D) Positive regulation of B cell activation 
 
Affymetrix 



















1424638_at Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 12575 398 384 860 2.24 0.05 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 453 470 1045 2.22 0.002 
1437271_at Clcf1 cardiotrophin-like cytokine factor 1 56708 295 238 128 -1.85 0.02 
1426297_at Tcf3 transcription factor 3 21423 968 856 444 -1.93 0.004 
1417372_a_at Peli1 pellino 1 67245 2397 2213 1076 -2.06 0.004 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 3122 3033 1420 -2.14 0.002 
1416335_at Mif macrophage migration inhibitory factor 17319 4803 4861 2252 -2.16 0.005 
1449361_at Tbx21 T-box 21 57765 403 359 160 -2.24 0.005 
1417371_at Peli1 pellino 1 67245 1567 1680 705 -2.38 0.001 
1460415_a_at Cd40 CD40 antigen 21939 701 556 212 -2.62 0.007 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 3033 2499 950 -2.63 0.01 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 3396 3793 1410 -2.69 0.003 
1436861_at Il7 interleukin 7 16196 359 369 129 -2.86 0.006 
1417597_at Cd28 CD28 antigen 12487 1260 1540 446 -3.45 0.003 
1437025_at Cd28 CD28 antigen 12487 806 829 196 -4.23 0.0008 
 
E) B cell proliferation 
 
Affymetrix 



















1455332_x_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 714 649 2245 3.46 0.0009 
1435476_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 1530 1454 3572 2.46 0.001 
1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 2049 2053 5035 2.45 0.001 
1451941_a_at Fcgr2b Fc receptor, IgG, low affinity IIb 14130 667 736 1782 2.42 0.01 
1424638_at Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 12575 398 384 860 2.24 0.05 
1460255_at Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
24099 453 470 1045 2.22 0.002 
1449839_at Casp3 caspase 3 12367 1413 1148 666 -1.72 0.01 
1437271_at Clcf1 cardiotrophin-like cytokine factor 1 56708 295 238 128 -1.85 0.02 
1426297_at Tcf3 transcription factor 3 21423 968 856 444 -1.93 0.004 
1417372_a_at Peli1 pellino 1 67245 2397 2213 1076 -2.06 0.004 
1427007_at Sash3 SAM and SH3 domain containing 3 74131 3122 3033 1420 -2.14 0.002 
1416335_at Mif macrophage migration inhibitory factor 17319 4803 4861 2252 -2.16 0.005 
1421205_at Atm ataxia telangiectasia mutated homolog (human) 11920 682 707 319 -2.22 0.01 
1451507_at Mef2c myocyte enhancer factor 2C 17260 645 583 255 -2.29 0.05 
1448575_at Il7r interleukin 7 receptor 16197 2453 3546 1546 -2.29 0.003 
1417371_at Peli1 pellino 1 67245 1567 1680 705 -2.38 0.001 
1460415_a_at Cd40 CD40 antigen 21939 701 556 212 -2.62 0.007 
1419307_at Tnfrsf13c tumor necrosis factor receptor superfamily, member 
13c 
72049 3033 2499 950 -2.63 0.01 
1436861_at Il7 interleukin 7 16196 359 369 129 -2.86 0.006 
1421028_a_at Mef2c myocyte enhancer factor 2C 17260 691 763 262 -2.92 0.02 
1419334_at Ctla4 cytotoxic T-lymphocyte-associated protein 4 12477 488 472 147 -3.21 0.002 
1448576_at Il7r interleukin 7 receptor 16197 533 878 270 -3.25 0.02 
1452389_at Cd27 CD27 antigen 21940 444 489 138 -3.53 0.005 
 
F) B cell differentiation 
 
Affymetrix 



















1434694_at Lrrc8a leucine rich repeat containing 8A 241296 456 450 987 2.20 0.005 
1437271_at Clcf1 cardiotrophin-like cytokine factor 1 56708 295 238 128 -1.85 0.02 
1426297_at Tcf3 transcription factor 3 21423 968 856 444 -1.93 0.004 
1421142_s_at Foxp1 forkhead box P1 108655 738 723 333 -2.17 0.003 
1421205_at Atm ataxia telangiectasia mutated homolog (human) 11920 682 707 319 -2.22 0.01 
1455242_at Foxp1 forkhead box P1 108655 1928 2227 986 -2.26 0.03 
1460188_at Ptpn6 protein tyrosine phosphatase, non-receptor type 6 15170 2532 2309 926 -2.49 0.02 
1419406_a_at Bcl11a B cell CLL/lymphoma 11A (zinc finger protein) 14025 883 809 306 -2.64 0.03 
1416296_at Il2rg interleukin 2 receptor, gamma chain 16186 3396 3793 1410 -2.69 0.003 
1421141_a_at Foxp1 forkhead box P1 108655 487 581 197 -2.94 0.007 
1450829_at Tnfaip3 tumor necrosis factor, alpha-induced protein 3 21929 147 218 65 -3.38 0.03 
 
Summary table I. Detailed mRNA profiles of spleen, blood, lymph nodes and aorta of WT and ApoE-/- mice. 
(A) The tables indicate differential gene expression profiles in WT and ApoE-/- aorta (A1), spleen (A2) and blood (A3).  
(B) The tables indicate differential gene expression profiles of indicated adventitia cluster (B1), plaque-ATLO cluster (B2), and lymph node cluster 
(B3) for GO terms: B cell mediated immunity, B cell activation, immunoglobulin, positive regulation of B cell mediated immunity, positive regulation 
of B cell activation, B cell proliferation, and B cell differentiation. One way ANOVA or student’s t test was applied. 
	  
